Page last updated: 2024-12-11

palonosetron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6337614
CHEMBL ID1189679
CHEBI ID85161
SCHEMBL ID3746
SCHEMBL ID13391549
MeSH IDM0221985

Synonyms (59)

Synonym
HY-A0018
aloxi
aloxi (tn)
palonosetron
DB00377
(3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one
2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz(de)isoquinolin-1-one
(s-(r*,r*))-2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz(de)isoquinolin-1-one
1h-benz(de)isoquinolin-1-one, 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-, (s-(r*,r*))-
2-qhbiqo
D07175
palonosetron (inn)
135729-61-2
nsc-743769
(3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one
chebi:85161 ,
(-)-palonosetron
palonosetron, (3as, 3s)-
CHEMBL1189679
palonosetron [inn]
nsc 743769
5d06587d6r ,
unii-5d06587d6r
CPZBLNMUGSZIPR-NVXWUHKLSA-N
AKOS015967749
bdbm50417287
CS-0385
S5740
AKOS025311243
palonosetron [who-dd]
palonosetron [mi]
palonosetron [vandf]
1h-benz(de)isoquinolin-1-one, 2-(3s)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, (3as)-
AB00698542-05
SCHEMBL3746
gtpl7486
DTXSID5048342 ,
SCHEMBL13391549
palonosetronum
Q-100993
AB00698542_07
mfcd07783848
(s)-2-((s)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one
BCP07225
AS-35217
1021481-16-2
(3~{a}~{s})-2-[(3~{s})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{h}-benzo[de]isoquinolin-1-one
palonosetron; aloxi
HMS3886A22
NCGC00271490-05
(3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one.
P-226
1h-benz(de)isoquinolin-1-one, 2-((3s)-1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-, (3as)-
(5s)-3-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.0,5,13]trideca-1(12),9(13),10-trien-2-one
EN300-220764
Z2185274784
(3as)-2-((3s)-1-azabicyclo(2.2.2)octan-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benzo(de)isoquinolin-1-one
a04aa05
dtxcid6028317

Research Excerpts

Overview

Palonosetron (Aloxi) is a potent second generation 5-HT(3) receptor antagonist whose mechanism of action is not yet fully understood. It is an effective antiemetic in chemotherapy-induced nausea and vomiting (CINV)

ExcerptReferenceRelevance
"Palonosetron (Aloxi) is a potent second generation 5-HT(3) receptor antagonist whose mechanism of action is not yet fully understood. "( Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
De Rienzo, F; Del Cadia, M; Lummis, SC; Menziani, MC; Thompson, AJ; Weston, DA, 2013
)
2.15
"Palonosetron is a medication that is now licensed by the Food and Drug Administration for the treatment of this ailment."( Effect of Palonosetron on Physical Symptoms of Surgical Patients: A Systematic Review and Meta-Analysis.
Chu, R, 2022
)
1.85
"Palonosetron is a new generation 5-HT"( Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z, 2018
)
2.64
"Palonosetron is an effective antiemetic in chemotherapy-induced nausea and vomiting (CINV), but has yet to be studied in the radiation setting. "( A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.
Barnes, E; Chan, S; Chow, E; Chung, H; DeAngelis, C; Drost, L; Ganesh, V; Pasetka, M; Pulenzas, N; Tsao, M; Wan, BA; Yee, C; Zaki, P; Zhang, L, 2018
)
2.25
"Palonosetron is a new, potent and long-acting 5HT3-receptorsantagonist that had been approved by the FDA for use in postoperative nausea and vomiting (PONV) prophylaxis. "( Efficacy of Palonosetron as Antiemetic Prophylaxis for Post Operative Patients.
Ahamed, S; Begum, M; Begum, R; Chowdhury, MG; Hossain, M; Hossain, MM; Shuvo, FR, 2019
)
2.34
"Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited. "( Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019
)
3.4
"Palonosetron is a new agent in the class of 5-HT3 receptor antagonists (5-HT3RAs), and differs from the other agents by its higher receptor-binding affinity and longer half-life."( An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Fabi, A; Malaguti, P, 2013
)
1.48
"Palonosetron acts as a pseudo-irreversible antagonist causing prolonged inhibition of 5-HT₃ receptors due to its very slow dissociation. "( Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Connolly, CN; Hothersall, JD; Moffat, C, 2013
)
2.1
"Palonosetron is a potent 5-HT₃ receptor antagonist with a unique structure and some unusual properties. "( Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis, SC; Thompson, AJ, 2013
)
2.1
"Palonosetron is a recently introduced 5-HT3 receptor antagonist for postoperative nausea and vomiting. "( Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
Choi, EK; Hong, DM; Jeon, Y; Jung, YS; Kim, HJ; Lee, HC; Lee, J; Min, JJ; Oh, S, 2014
)
2.25
"Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though it could have useful clinical applications. "( Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B, 2014
)
2.08
"Palonosetron(Palo)is a second-generation 5-hydroxytryptamine 3 receptor antagonist(5-HT3RA)effective in suppressing chemotherapy-induced nausea and vomiting in both acute and delayed phases.Most studies have reported Palo as an effective antiemetic for cisplatin(CDDP)chemotherapy(≥50mg/m2)administered on an intermittent basis.To assess the antiemetic efficacy of Palo, we performed a retrospective study in 16 patients with lung cancer who received Palo with split-dose CDDP, ifosfamide, and irinotecan(CPT-11)triple combination(CIC)therapy at Sapporo Minami-Sanjo Hospital between October 2010 and January 2012.T he CIC regimen consisted of CPT-11(50-60mg/m2)administered on days 1, 8, and 15, in addition to CDDP(15-20mg/m2)and ifosfamide(1,500mg/kg)for 4 consecutive days.On day 1, ramosetron was replaced with Palo in patients who had insufficient antiemetic control in accordance with guidelines on the management of highly emetogenic chemotherapy(HEC).There was a lower incidence of grade 1 or higher nausea(62.5%)in patients in the Palo-combination group than in those in the non-Palo-combination group(87.5%).No incidence of grade 3 or higher nausea was reported in either group.On the fifth day of chemotherapy, the incidence of nausea was significantly lower in the Palo-combination group(43.8%)than in the non-Palo-combination group(81.3%)(p<0.05).In addition, there was a significant decrease in the number of days of incidence and a significant increase in the number of days since the last episode was observed in the Palo-combination group.These results suggest that Palo, in particular, decreases the incidence of nausea and extends the number of days since its occurrence; moreover, it is effective in accelerating recovery.In conclusion, this study suggests that Palo exhibits excellent antiemetic efficacy in patients administered split doses of CDDP. "( [Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
Fujita, A; Hatsuyama, T; Kobayashi, M; Sato, H; Sekine, K; Umehara, K; Wakamoto, A, 2016
)
2.15
"Palonosetron is a potent 5-HT"( Palonosetron-5-HT
Lillestol, RK; Lummis, SC; Price, KL; Ulens, C, 2016
)
3.32
"Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV)."( Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Arora, MK; Borle, A; Gouda, D; Goudra, B; Makkar, JK; Singh, PM; Sinha, A; Trikha, A, 2016
)
2.26
"Palonosetron is a 5-HT(3)-receptor antagonist (5-HT(3)-RA) that has been shown to be superior to other 5-HT(3)-RAs in phase III clinical trials for the prevention of acute, delayed, and overall chemotherapy-induced nausea and vomiting. "( Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Alt, J; Cantoreggi, S; Massuda, EB; Rojas, C; Rubenstein, E; Sebastiani, S; Slusher, B; Snyder, SH; Stathis, M; Thomas, AG; Zhang, J, 2008
)
3.23
"Palonosetron is a safe and effective antiemetic treatment in children, as well as being cost effective."( Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA, 2008
)
3.23
"Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to ondansetron in preventing CINV in patients receiving highly emetogenic chemotherapy. "( Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Aogi, K; Inoue, K; Kitagawa, C; Mitsuhashi, S; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H, 2009
)
3.24
"Palonosetron is a second-generation 5-HT(3) receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT(3) receptor antagonists."( Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Navari, RM, 2009
)
1.07
"Palonosetron is a new representative of the serotonin-3 receptor antagonists but without the hoped for superiority on the 2nd and 3rd postoperative days."( [Postoperative nausea and vomiting--what's new in anti-emetic pharmacotherapy?].
Eberhart, LH; Kranke, P; Wallenborn, J, 2009
)
1.07
"Palonosetron is a new generation 5-HT(3) RA with indication not only acute but also delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC)."( A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M, 2009
)
1.36
"Palonosetron is a 5-HT(3) receptor antagonist that has demonstrated superiority in preventing both acute and delayed emesis when compared to older first generation 5-HT(3) receptor antagonists. "( Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Alt, J; Cantoreggi, S; Rojas, C; Rubenstein, EB; Sebastiani, S; Slusher, BS; Stathis, M; Thomas, AG; Zhang, J, 2010
)
3.25
"Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists. "( Palonosetron: in the prevention of nausea and vomiting.
Scott, LJ; Yang, LP, 2009
)
3.24
"Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor."( Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Cao, R; Dong, X; Huang, J; Liu, L, 2011
)
2.53
"Palonosetron is a second-generation 5-HT(3) receptor antagonist that has recently been approved for prophylaxis against PONV."( Different doses of palonosetron for the prevention of postoperative nausea and vomiting in children undergoing strabismus surgery.
Aksu, R; Bicer, C; Boyaci, A; Dogan, H; Madenoglu, H; Ulgey, A; Yildiz, K, 2011
)
1.42
"Palonosetron is a second-generation 5-HT(3) receptor antagonist with proven efficacy for both acute and delayed CINV."( A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi, K; Inoue, K; Katakami, N; Kuranami, M; Masuda, N; Mizutani, M; Sakai, H; Yanagita, Y; Yoshizawa, H, 2012
)
1.34
"Palonosetron is a novel 5-hydroxytryptamine(3) (5 HT(3)) receptor antagonist, which has been shown to be superior to first generation 5 HT(3) receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. "( Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
Araz, M; Ata, OY; Dogan, U; Yavas, C; Yavas, G, 2012
)
2.17
"Palonosetron is a long-acting, highly potent, second-generation serotonin receptor antagonist."( Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N, 2012
)
1.37
"Palonosetron is a new potent 5-hydroxytryptamine 3 antagonist. "( Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study.
Joo, J; Kim, JE; Lee, Y; Moon, YE, 2012
)
2.09
"Palonosetron is a 5-HT(3) receptor antagonist approved for both the prevention of acute and delayed chemotherapy induced nausea and vomiting after moderately emetogenic chemotherapy."( Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Pietra, C; Rojas, C; Slusher, BS; Stathis, M, 2012
)
1.33
"Palonosetron is a second-generation 5-HT3 receptor antagonist with a prolonged duration of action and a higher receptor binding affinity than first-generation agents."( [Evaluation of palonosetron for the prevention of nausea and vomiting induced by colon cancer chemotherapy].
Nakayama, Y; Shinohara, Y; Takahashi, K; Torigoe, T; Yamaguchi, K, 2012
)
1.45
"Palonosetron (Aloxi) is a 5-HT(3)-receptor antagonist antiemetic indicated for the prevention of acute and delayed nausea and vomiting following moderately emetogenic chemotherapy and for acute nausea and vomiting following highly emetogenic chemotherapy. "( Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Grunberg, SM; Koeller, JM, 2003
)
3.2
"Palonosetron is an effective and well-tolerated agent for the prevention of CINV following highly emetogenic chemotherapy, with 3 and 10 microg/kg identified as the lowest effective palonosetron doses."( Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P, 2004
)
2.03
"Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. "( Palonosetron.
Scott, LJ; Siddiqui, MA, 2004
)
3.21
"Palonosetron HCl is a selective 5-HT(3) receptor antagonist used for the prevention of chemotherapy-induced nausea and vomiting. "( Physical and chemical stability of palonosetron HCl in 4 infusion solutions.
Trissel, LA; Xu, QA, 2004
)
2.04
"Palonosetron is a new 5-HT3 receptor antagonist with a longer half life and a higher binding affinity than older 5-HT3 receptor antagonists."( Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari, RM,
)
0.85
"Palonosetron HCl is a selective 5-HT3 receptor antagonist used for the prevention of chemotherapy-induced nausea and vomiting. "( Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Trissel, LA; Zhang, Y, 2005
)
3.21
"Palonosetron is a new drug in the class of 5-HT (3) (serotonin) receptor antagonists."( [Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours].
Ihbe-Heffinger, A; Lordick, F; Peschel, C, 2005
)
1.05
"Palonosetron is a second-generation 5-HT(3) receptor antagonist with a prolonged duration of action and higher receptor binding affinity than first-generation agents (ondansetron, granisetron, and dolasetron). "( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
2.09
"Palonosetron is a unique 5-HT3 receptor antagonist whose distinctive pharmacologic characteristics (ie, high 5-HT3 receptor binding affinity, prolonged half-life) result in superior clinical benefit."( Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein, EB, 2004
)
2.49
"Palonosetron is a 5-HT3 receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT3 receptor antagonists."( Emerging drugs for chemotherapy-induced emesis.
Navari, RM; Province, PS, 2006
)
1.06
"Palonosetron is a potent, selective 5-HT(3) receptor antagonist effective in the prevention of acute and delayed chemotherapy-induced nausea and vomiting. "( Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects.
Apseloff, G; DeGroot, T; Shah, A, 2006
)
2
"Palonosetron is a 5-HT3 receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT3 receptor antagonists."( Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari, RM, 2006
)
2.5
"Palonosetron is a new generation 5-HT3-receptor antagonist with a significantly prolonged half-life and a once-a-day administration compared to the conventional setrons. "( Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Andel, J; Angleitner-Boubenizek, L; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Petru, E; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Steger, G; Thödtmann, R; Zabernigg, A, 2008
)
2.05

Effects

Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor. Oral palonosets has a similar efficacy and safety profile as IV palonasetron 0.25 mg and may be the preferred formulation in certain clinical situations.

Palonosetron has been approved for the prevention of acute CINV in patients receiving either moderately or highly emetogenic chemotherapy. It has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor.

ExcerptReferenceRelevance
"Palonosetron has a longer half-life and a higher binding affinity than the first generation 5-HT3 receptor antagonists. "( Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari, RM, 2009
)
3.24
"Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor."( Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.
Mamoudou, AD; Nadaraja, S; Rosthoej, S; Schroeder, H; Thomassen, H; Wehner, PS, 2012
)
2.54
"Oral palonosetron has a similar efficacy and safety profile as IV palonosetron 0.25 mg and may be the preferred formulation in certain clinical situations. "( Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Boccia, R; Franco-Gonzales, E; Grunberg, S; Rubenstein, E; Voisin, D, 2013
)
1.24
"Palonosetron has demonstrated non-inferiority to ondansetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients in the United States and Europe. "( Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Fujisaki, H; Goto, H; Hara, J; Ishida, Y; Koga, Y; Koh, K; Kosaka, Y; Kumamoto, T; Matsumoto, K; Mochizuki, S; Suzuki, R; Yuza, Y, 2021
)
2.39
"Palonosetron has been approved for the prevention of acute CINV in patients receiving either moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV in patients receiving moderately emetogenic chemotherapy."( The current status of the use of palonosetron.
Navari, R, 2013
)
1.39
"Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy. "( Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016
)
3.32
"Palonosetron has potent and long-acting antiemetic effects for postoperative nausea and vomiting (PONV). "( A randomized, double-blind trial evaluating the efficacy of palonosetron with total intravenous anesthesia using propofol and remifentanil for the prevention of postoperative nausea and vomiting after gynecologic surgery.
Bang, YS; Kim, YU; Oh, D; Park, SK; Shin, EY, 2016
)
2.12
"Palonosetron has a longer half-life and a higher binding affinity than the first generation 5-HT3 receptor antagonists. "( Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari, RM, 2009
)
3.24
"Palonosetron has a half life of 36-42 hours and has higher affinity and selectivity to the 5-HT(3) receptor."( Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.
Mamoudou, AD; Nadaraja, S; Rosthoej, S; Schroeder, H; Thomassen, H; Wehner, PS, 2012
)
2.54
"Oral palonosetron has a similar efficacy and safety profile as IV palonosetron 0.25 mg and may be the preferred formulation in certain clinical situations. "( Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Boccia, R; Franco-Gonzales, E; Grunberg, S; Rubenstein, E; Voisin, D, 2013
)
1.24

Actions

ExcerptReferenceRelevance
"Palonosetron did not increase the rate of perioperative cardiovascular complications, and can therefore be used safely during anesthetic induction."( Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study.
Hong, DM; Jeon, Y; Jung, HJ; Jung, SY; Kim, BG; Kim, HJ; Kim, TK; Kwon, K; Min, JJ; Park, BJ, 2015
)
1.53

Treatment

Pretreatment of palonosetron with venous occlusion may attenuate rocuronium-induced withdrawal movement as effective as the use of lidocaine. Treatment with palonasetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV.

ExcerptReferenceRelevance
"Pretreatment with palonosetron significantly reduced many signs of experimentally-induced opioid withdrawal. "( Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.
Chu, LF; Clark, JD; D'Arcy, N; Encisco, EM; Erlendson, MJ; Peltz, G; Rincon-Cruz, L; Yu, JJ, 2017
)
2.23
"Pretreatment of palonosetron with venous occlusion may attenuate rocuronium-induced withdrawal movement as effective as the use of lidocaine. "( [The effect of palonosetron on rocuronium-induced withdrawal movement].
Chung, SY; Jeon, Y; Kim, JH; Kwak, KH; Park, KB; Yi, J,
)
0.83
"Treatment with palonosetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV and treatment of breakthrough emesis in the setting of HD-CT."( Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Bianchini, C; Bonanno, V; Crescimanno, A; Musso, M; Perrone, T; Polizzi, V; Porretto, F; Scalone, R, 2010
)
2.14

Toxicity

Palonosetron is a safe and effective antiemetic treatment in children, as well as being cost effective. The incidence and severity of adverse events (AEs) were similar between subjects receiving palonosETron and those receiving placebo, with no dose-dependent incidences. Only two patients experienced treatment-related adverse events.

ExcerptReferenceRelevance
" Palonosetron was well-tolerated, with no dose-response effect evident for the incidence or intensity of adverse events."( Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P, 2004
)
1.5
" The incidence and severity of adverse events (AEs) were similar between subjects receiving palonosetron and those receiving placebo, with no dose-dependent incidences."( Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.
Cyong, JC; Parisi, S; Shah, A; Stoltz, R, 2004
)
0.81
"25 mg was safe and well tolerated."( Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.56
"Emesis and nausea are common adverse effects of chemotherapy."( Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA, 2008
)
1.79
" They also reported any possible adverse effects."( Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA, 2008
)
1.79
" No adverse effects were reported."( Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA, 2008
)
1.79
"Palonosetron is a safe and effective antiemetic treatment in children, as well as being cost effective."( Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA, 2008
)
3.23
" Adverse events were mostly mild to moderate, with quite low rates among the two groups."( The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Huang, Y; Liang, H; Liu, D; Liu, W; Si, X; Wang, L; Yu, Z; Zhang, H, 2009
)
0.65
" The primary endpoint was the incidence rate of adverse events (AEs)."( A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi, K; Inoue, K; Katakami, N; Kuranami, M; Masuda, N; Mizutani, M; Sakai, H; Yanagita, Y; Yoshizawa, H, 2012
)
0.62
" Palonosetron was well tolerated; only two patients experienced treatment-related adverse events."( Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
Ahmed, R; Cox, D; Hesketh, PJ; Komorowski, AW; Morrow, G, 2012
)
1.6
"Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC."( Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M, 2014
)
0.4
" Secondary endpoints were the percentage of patients suffering from 5-HT(3)RA-related adverse events."( Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Chan, KK; Chow, E; Deangelis, C; Lam, H; Poon, M; Popovic, M; Pulenzas, N; Tsao, M; Warr, DG; Yip, C; Zhang, L, 2014
)
0.71
" Repeated treatment with palonosetron was safe and well tolerated by patients who received highly or moderately emetogenic anticancer chemotherapy."( Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.
Goto, T; Hara, S; Ikari, Y; Ishitsuka, K; Katsuya, H; Masaki, M; Nakashima, Y; Ogata, K; Sato, E; Takamatsu, Y; Tamura, K; Tanaka, T, 2014
)
0.93
" Adverse events were comparable across groups with no dose response."( Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Alyasova, A; Bondarenko, I; Gralla, RJ; Hesketh, PJ; Lisyanskaya, A; Palmas, M; Rizzi, G; Rossi, G, 2014
)
0.64
" Safety was assessed primarily by adverse events (AEs), including cardiac AEs; efficacy by complete response (CR: no emesis, no rescue)."( A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Balser, C; Borroni, ME; Bosnjak, SM; Gralla, RJ; Hontsa, A; Jordan, K; Rizzi, G; Rossi, G, 2014
)
0.62
" Incidence and severity of nausea were assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) and a subjective rating scale completed by patients."( Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S, 2014
)
0.65
" The reported adverse drug reactions were hiccups (13."( Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S, 2014
)
0.65
" The most common adverse reactions were constipation and fatigue (reported by three patients each)."( Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H, 2014
)
0.65
" The incidence of nausea and vomiting, severity of nausea, requirements for rescue anti-emetics, and adverse effects at 2, 24, and 72 h after drug administration were evaluated."( A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.
Choi, WJ; Hahm, TS; Hwang, JW; Kim, DK; Kim, WH; Kim, YH; Oh, EJ; Ryu, JH; Yon, JH; Yoo, BH, 2015
)
0.63
" The incidence of adverse events was not different between the groups."( A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.
Choi, WJ; Hahm, TS; Hwang, JW; Kim, DK; Kim, WH; Kim, YH; Oh, EJ; Ryu, JH; Yon, JH; Yoo, BH, 2015
)
0.63
"The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron."( 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Brygger, L; Herrstedt, J, 2014
)
0.6
" There were no grade 3 or 4 adverse events."( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016
)
0.68
" Treatments were generally well tolerated with few grade 3 adverse events none of which were related to the study treatment; the most common grade 3 adverse event during the 5 weeks of treatment was diarrhoea (11 [9%] of 118 patients in the fosaprepitant group vs six [5%] of 116 patients in the placebo group)."( Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E, 2016
)
0.43
" Both treatments were safe and well tolerated."( Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E, 2016
)
0.43
" Patients reported adverse effects in Common Toxicity Criteria for Adverse Events diaries; recorded vomiting, nausea, and rescue medication use in diaries (which were used to assess cRINV-CR); and reported QoL 4 days/week using the Modified Functional Living Index-Emesis (M-FLIE) and Osoba nausea and vomiting/retching modules."( Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016
)
0.67
"Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ."( Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016
)
0.67
" Safety was assessed primarily by treatment-emergent adverse events (AEs) and electrocardiograms."( Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Andric, Z; Gralla, RJ; Karthaus, M; Kowalski, D; Navari, R; Radic, J; Rizzi, G; Roeland, E; Schwartzberg, L; Voisin, D, 2018
)
0.7
"Results suggest that oral NEPA is effective and safe in preventing CINV in patients with gynecological cancers treated with cisplatin- or carboplatin-based CT."( Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Borroni, ME; Bošnjak, SM; Jordan, K; Rizzi, G; Stamatovic, L, 2018
)
0.74
" NEPA was well tolerated with no treatment-related adverse events reported."( Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Benedetti, F; Bonizzoni, E; Bozzoli, V; Capria, S; Chiusolo, P; Codega, P; Cupelli, L; Cupri, A; De Risi, C; Di Renzo, N; Federico, V; Guarini, A; Matera, R; Mazza, P; Mengarelli, A; Messa, AR; Musso, M; Pastore, D; Perrone, T; Scimè, R; Seripa, D; Specchia, G, 2022
)
1
" Treatment-related adverse events (AEs) were recorded."( Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Abdul Rahman, MHFB; Abdullah, MM; Ahmad Annuar, MA; Ahmad Badruddin, RBA; Chong, KJ; Lai, CNB; Lam, KS; Lau, KL; Low, JSH; Md Yusof, M; Ng, SC; Nonis, JG; Yap, BK, 2022
)
0.95
"We explored the adverse drug reaction signals of drug-induced neutropenia (DIN) and drug-induced agranulocytosis (DIA) in hospitalized patients and evaluated the novelty of these correlations."( Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records.
Liu, A; Sun, C; Xiang, Y; Yuan, Y; Zhao, L, 2023
)
0.91

Pharmacokinetics

Palonosetron may provide a clinical advantage over other 5-HT(3) antagonists. There were no significant pharmacokinetic interactions between netupitant and palonosETron.

ExcerptReferenceRelevance
" Dose-proportional increases in pharmacokinetic parameters and a long plasma half-life (43."( Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P, 2004
)
0.59
" The plasma concentration profile of palonosetron, as represented by a half-life of approximately 40 hours, may provide a clinical advantage over other 5-HT(3) antagonists."( Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.
Cyong, JC; Parisi, S; Shah, A; Stoltz, R, 2004
)
0.86
" Serial plasma samples were collected on days 1 and 3 for pharmacokinetic determinations."( Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.56
" Blood for pharmacokinetic evaluations was collected through 168 hours after palonosetron administration on days 1 and 15; safety was monitored through day 22."( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.88
" With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3."( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.65
"These results indicate no significant differences in pharmacokinetic parameters for palonosetron between the two treatments, and suggest that palonosetron can be safely coadministered with aprepitant with no alterations in the expected safety profile and no dosage adjustment necessary."( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.88
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" No significant differences were found between the pharmacokinetic parameters and urine accumulated excretory rate for male and female volunteers (P>0."( Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study.
Li, P; Liu, L; Ma, P; Tong, W; Wang, J; Wang, Y; Wu, C, 2012
)
0.59
"There were no significant pharmacokinetic interactions between netupitant and palonosetron."( Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W, 2013
)
0.84
" We compared pharmacokinetic parameters including AUC0-24h, t1/2, and Cmax observed with each route of administration by analysis of variance (ANOVA)."( Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B, 2014
)
0.63
" Cmax was lower with SC than with IV route and was reached 15 minutes following SC administration."( Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B, 2014
)
0.63
" The method is simple, rapid, and has been applied successfully to a pharmacokinetic study of netupitant and palonosetron in healthy volunteers."( Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study.
Chen, H; Du, J; Li, H; Li, S; Li, W; Ni, Y; Xu, M; Zhou, Y, 2016
)
0.86
" This study evaluated the pharmacokinetic profiles of netupitant and palonosetron."( Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Bernareggi, A; Gilmore, J, 2019
)
0.99
" This study aimed to examine whether fixed dosing is more appropriate than body size-based dosing through the development of a population pharmacokinetic model and model-based simulations."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
" A population pharmacokinetic analysis was performed by non-linear mixed-effects modeling, and the area under the curves (AUCs) for fixed dosing and body size-based dosing were simulated."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
"The pharmacokinetics of palonosetron were best described by the three-compartment model, and lean body weight (LBW) was the most significant covariate for all pharmacokinetic parameters."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
1.11

Compound-Compound Interactions

Palonosetron (PALO), a second-generation 5-HT3 receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline and cyclophosphamide (AC) moderately-emetogenic chemotherapy (MEC)

ExcerptReferenceRelevance
"This is a randomized, double-blind, dose-ranging study in patients receiving highly emetogenic chemotherapy (HEC) to evaluate the safety, efficacy, and pharmacokinetics of palonosetron, in combination with dexamethasone."( A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
Hida, T; Imamura, F; Katakami, N; Kubota, K; Maemondo, M; Masuda, N; Segawa, Y; Sekine, I; Shibuya, M; Takeo, S, 2009
)
0.87
" Three studies were designed to evaluate the potential drug-drug interaction of netupitant with palonosetron and of the fixed dose combination of netupitant and palonosetron, NEPA, with an inhibitor (ketoconazole), an inducer (rifampicin) and a substrate (oral contraceptives) of CYP3A4."( Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W, 2013
)
0.83
" In study 2, 36 subjects received NEPA alone (day 1) and in combination with ketoconazole or rifampicin."( Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W, 2013
)
0.61
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014
)
0.88
"Patients who received highly emetogenic chemotherapy were randomly assigned to a treatment group (60 patients) treated with EANI combined with hydrochloride palonosetron, and control group (also 60 patients) given only hydrochloride palonosetron."( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014
)
0.85
"EANI combined with hydrochloride palonosetron for prevention of nausea and vomiting induced by chemotherapy could be more effective than hydrochloride palonosetron alone, and can be recommended for use in prevention and treatment of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014
)
0.94
"The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1-3 in combination with palonosetron (PALO), a second-generation 5-HT3 receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline and cyclophosphamide (AC) moderately-emetogenic chemotherapy (MEC)."( Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S, 2015
)
0.82
"The aim of the present study was to evaluate the efficacy and toxicity of palonosetron (PAL) and dexamethasone (DEX) on day 1 only in patients with gynecologic cancer receiving paclitaxel combined with carboplatin (TC)."( Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Furukawa, N; Ito, F; Kanayama, S; Tanase, Y, 2015
)
2.09
" This review evaluates potential drug-drug interactions between NETU or NEPA and CYP3A4 substrates/inducers/inhibitors or P-gp substrates in healthy subjects."( Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Calcagnile, S; Cox, D; Kashef, K; Lanzarotti, C; Natale, JJ; Rossi, G; Spinelli, T, 2016
)
0.66
" Oral olanzapine (5 mg) was administered with triplet therapy a day prior to cisplatin administration and on days 1-5."( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016
)
0.68
"Preventive use of olanzapine combined with triplet therapy gives better results than those from previously reported studies of triplet therapy."( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016
)
0.68
" Eligible patients were women with uterine cervical, endometrial or ovarian cancer scheduled to receive conventional TC regimen or dose-dense TC regimen; 116 patients were randomly assigned to receive palonosetron in combination with 1-day DEX or 3-day DEX."( Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
Hayakawa, O; Iwasaki, M; Matsuura, M; Mizunuma, M; Nishikawa, A; Saito, T; Satohisa, S; Tanaka, R; Tanaka, S; Teramoto, M, 2015
)
2.05
"To investigate the efficacy and safety of olanzapine in combination with palonosetron and dexamethasone for patients receiving cisplatin (≥50 mg/m(2) ), because this antiemetic therapy has not been sufficiently examined in patients receiving cisplatin."( A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Asano, C; Haegawa, I; Horio, Y; Kadowaki, S; Kajita, M; Komori, A; Maeda, A; Mizutani, A; Muro, K; Narita, Y; Nomura, M; Oze, I; Taniguchi, H; Ura, T; Yoshida, T, 2016
)
0.91
"Olanzapine combined with palonosetron and dexamethasone did not prevent chemotherapy-induced nausea and vomiting induced by cisplatin as expected."( A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Asano, C; Haegawa, I; Horio, Y; Kadowaki, S; Kajita, M; Komori, A; Maeda, A; Mizutani, A; Muro, K; Narita, Y; Nomura, M; Oze, I; Taniguchi, H; Ura, T; Yoshida, T, 2016
)
0.98
"Background Two pivotal Phase III trials compared the efficacy of palonosetron, ondansetron and granisetron, combined with dexamethasone, for the prevention of nausea and vomiting following highly emetogenic chemotherapy."( Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B, 2017
)
0.69
"A systematic review and meta-analysis of published randomized controlled trials was performed to update the present evidence about the safety and efficacy of dexamethasone combined with other antiemetics versus single antiemetics for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"Pooled data from 14 RCTs (1542 patients) favored dexamethasone combined with other antiemetics over single antiemetics as a prophylaxis against postoperative nausea and vomiting after laparoscopic cholecystectomy in the early postoperative period (OR = 0."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"Dexamethasone combined with other antiemetics provided better prophylaxis than single antiemetics against postoperative nausea and vomiting after laparoscopic cholecystectomy."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"The aim of this study was to evaluate aprepitant in combination with palonosetron as compared to palonosetron alone for the prevention of postoperative nausea and vomiting (PONV) in female patients receiving fentanyl- based intravenous patient-controlled analgesia (IV-PCA)."( Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia.
Chung, JW; Han, YM; Jun, MR; Kim, SI; Kim, YJ; Yoo, JH, 2018
)
1
"Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA."( Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia.
Chung, JW; Han, YM; Jun, MR; Kim, SI; Kim, YJ; Yoo, JH, 2018
)
1.07
"Although dexamethasone in combination with other antiemetic agents has been used to prevent chemotherapy-induced nausea and vomiting (CINV), it is of clinical importance to minimize total dose of dexamethasone in patients undergoing multiple cycles of emetogenic chemotherapy."( One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
Aapro, M; Celio, L; Furukawa, N; Komatsu, Y; Kosaka, Y; Oba, K; Okada, Y; Okita, K; Yuki, S, 2019
)
0.76
" We conducted a Bayesian network meta-analysis to compare the prophylactic efficacy of these agents in combination with PALO-DEX."( Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Aapro, M; Abraham, I; Alatawi, Y; Alharbi, AS; Alhifany, AA; Almutairi, AR; Babiker, H; Cheema, E; MacDonald, K; McBride, A; Shahbar, A, 2020
)
0.78
"To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
1.11
"75 mg (day 1) or granisetron 1 mg (day 1) combined with dexamethasone (12 mg at day 1, 8 mg at day 2 and day 3) and Fos 150 mg (day 1) before receiving AC-based regimen in a double-blind study."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
0.8
"In combination with dexamethasone and Fos, this study suggests that palonosetron is not better than granisetron in chemo-naive patients with primary breast cancer receiving AC-based regimen."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
1.04
"25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)."( Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting.
Ahn, JS; An, HJ; Kang, JH; Kim, GM; Kim, HJ; Kim, JY; Koo, DH; Kwon, JH; Lee, H; Lee, YG; Park, KU; Seol, YM; Sohn, J; Song, H; Yang, JH; Yun, HJ, 2020
)
0.89
" Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients receiving HEC regimen, DEX sparing was not non-inferior in patients receiving cisplatin (CDDP)-based HEC regimens in subgroup analysis."( Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin
Arioka, H; Hida, N; Iihara, H; Inada, Y; Ishida, H; Izawa, N; Katada, C; Kawaguchi, T; Kazunori, H; Minatogawa, H; Miyaji, T; Morita, H; Nakajima, TE; Nawata, S; Ohno, Y; Shimomura, K; Sugawara, M; Tsuboya, A; Tsuda, T; Yamaguchi, T, 2020
)
0.94
" This study aimed to evaluate the antiemetic efficacy of palonosetron (PALO) over granisetron (GRA) in combination with dexamethasone for multiple highly emetogenic chemotherapy drugs (HEC), especially in chemotherapy regimens in Egyptian breast cancer patients and cisplatin-based regimens in other diseases."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
1.12
" All patients received dexamethasone in combination with the 5-HT3 receptor antagonist."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
0.88
"Palonosetron, combined with dexamethasone, is more effective than granisetron and dexamethasone combination against both acute and delayed emesis induced by highly emetogenic chemotherapy (HEC) cisplatin-based protocols and the combination of cyclophosphamide and anthracyclines (AC)."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
2.32

Bioavailability

SC netupitant and palonosetron have high absolute bioavailability (63%-87% and 97% respectively) Palono's bioavailability was similar when administered by either SC or IV route.

ExcerptReferenceRelevance
" In this study, we evaluate the bioavailability of SC palonosetron."( Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B, 2014
)
0.88
"Palonosetron bioavailability was similar when administered by either SC or IV route."( Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B, 2014
)
2.08
" The absolute bioavailability of the optimized patch was 43 % in rabbit and a good in vitro-in vivo correlation coefficient was obtained (R(2)=0."( Drug in adhesive patch of palonosetron: Effect of pressure sensitive adhesive on drug skin permeation and in vitro-in vivo correlation.
Fang, L; Hui, M; Liu, C; Quan, P, 2016
)
0.73
" netupitant and palonosetron have high absolute bioavailability (63%-87% and 97%, respectively)."( Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Bernareggi, A; Gilmore, J, 2019
)
1.11

Dosage Studied

Netupitant and palonosetron's benefits include a convenient dosage form, dual-targeted mechanism, and favorable side effect profile. Main limitations are cost and potential logistical issues surrounding administration.

ExcerptRelevanceReference
" Palonosetron was well-tolerated, with no dose-response effect evident for the incidence or intensity of adverse events."( Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P, 2004
)
1.5
" Acute and delayed nausea may also be improved by aprepitant when used in combination with a 5-HT3 and dexamethasone prechemotherapy or with daily dosing for 3-5 days following chemotherapy."( Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari, RM,
)
0.13
"This study evaluated the safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron."( Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.78
"These results indicate no significant differences in pharmacokinetic parameters for palonosetron between the two treatments, and suggest that palonosetron can be safely coadministered with aprepitant with no alterations in the expected safety profile and no dosage adjustment necessary."( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005
)
0.88
" In a single dosing study, palonosetron was highly effective in controlling CINV compared with a single dose of dolasetron or ondansetron in patients receiving moderately emetogenic chemotherapy."( Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari, RM, 2006
)
2.07
"The aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus dexamethasone in patients receiving highly emetogenic multiple-day cisplatin-based chemotherapy for germ cell tumors."( Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Brames, MJ; Bubalo, J; Cullen, MT; Dreicer, R; Einhorn, LH; Nichols, CR, 2007
)
2
"A dose-response trend in the proportion of patients with a CR was observed with increasing doses of palonosetron in the first 24 hrs."( A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting.
Candiotti, KA; Clerici, G; Joo Gan, T; Kovac, AL; Melson, TI, 2008
)
0.78
" Multiple-day dosing of palonosetron plus dexamethasone was safe and effective for prevention of emesis induced by 5-day cisplatin-based chemotherapy."( Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
Bajetta, E; Canova, S; Celio, L; Denaro, A; Gevorgyan, A,
)
0.77
" This study was carried out to determine the optimal dosage of palonosetron in combination with dexamethasone in patients in Japan."( A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M, 2009
)
0.87
" No dose-response relationship was observed regarding the CR rate in the acute phase."( A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M, 2009
)
0.63
"This study indicates a statistically nonsignificant trend for the dose-response relationship for antiemetic protection in the delayed and overall phases in AC/EC patients (the regimen currently considered to be more emetogenic than MEC)."( A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M, 2009
)
0.63
" The recommended dosing schedule of palonosetron for the control of CINV due to biochemotherapy is not known."( Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N, 2012
)
0.92
" We evaluated and compared, by palonosetron dosing schedule, the pattern and the severity of CINV during the first 7 days of treatment and the duration of the 21-day cycle as well as the impact on daily function with the Functional Living Index-Emesis."( Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N, 2012
)
0.94
"Both dosing schedules of palonosetron were tolerated well."( Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N, 2012
)
0.95
" The objective of the current work was to determine if palonosetron's ability to inhibit receptor signaling crosstalk would influence netupitant's inhibition of the SP-mediated response when the two drugs are dosed together."( Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Pietra, C; Rojas, C; Slusher, BS; Stathis, M, 2012
)
0.85
"The effectiveness of palonosetron without delayed dexamethasone dosing against emesis was investigated in patients scheduled to receive the corticosteroid-containing combination of doxorubicin and paclitaxel (AT) for 3 cycles."( Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F, 2013
)
0.71
"Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated."( Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Bonizzoni, E; Celio, L; Di Nicola, M; Gianni, AM; Magni, M; Mirabile, A, 2014
)
0.99
" Netupitant and palonosetron's benefits include a convenient dosage form, dual-targeted mechanism, and favorable side effect profile, while its main limitations are cost and potential logistical issues surrounding administration."( The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
Abramovitz, RB; Gaertner, KM, 2016
)
1.08
"A randomised dose-response study."( Evaluation of weight-adjusted doses of palonosetron for prevention of postoperative nausea and vomiting in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial.
Bala, I; Gandhi, K; Jain, D; Jain, K, 2016
)
0.7
"A prospective, randomized, double-blind, parallel controlled study was conducted in 0-18 years old cancer patients administered highly emetogenic chemotherapy, with different dosage of palonosetron or ondansetron, both followed by dexamethasone."( Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z, 2018
)
2.11
" Altogether, these data explain the lack of pharmacokinetic interactions between netupitant and palonosetron at absorption, binding, metabolic, or excretory level, thus highlighting their compatibility as the oral fixed combination NEPA, with administration convenience that may reduce dosing mistakes and increase treatment compliance."( Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Bernareggi, A; Gilmore, J, 2019
)
0.98
" This double-blind, randomized, Phase II study investigated the dose-response of oral netupitant in Japanese patients receiving highly emetogenic chemotherapy."( A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Ikeda, N; Inoue, K; Kagamu, H; Kubota, K; Minato, K; Ohyanagi, F; Osaki, A; Saeki, T; Sakai, H; Tamura, T; Tokuda, Y; Yamada, K, 2019
)
0.74
"No dose-response relationship of netupitant in terms of overall CR rate was observed in this study."( A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Ikeda, N; Inoue, K; Kagamu, H; Kubota, K; Minato, K; Ohyanagi, F; Osaki, A; Saeki, T; Sakai, H; Tamura, T; Tokuda, Y; Yamada, K, 2019
)
0.74
" This study aimed to examine whether fixed dosing is more appropriate than body size-based dosing through the development of a population pharmacokinetic model and model-based simulations."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
" A population pharmacokinetic analysis was performed by non-linear mixed-effects modeling, and the area under the curves (AUCs) for fixed dosing and body size-based dosing were simulated."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
" In simulations, the overall interindividual variability in AUC (0, 48 h) of fixed dosing was not much higher than that of body size-based dosing."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
"LBW-based dosing might be suitable for high-weight patients to avoid possible underdosing."( Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies.
Jeong, S; Kim, I; Lee, S; Pyeon, T; Rhee, J; Song, J, 2019
)
0.8
"This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin's lymphoma."( Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Benedetti, F; Bonizzoni, E; Bozzoli, V; Capria, S; Chiusolo, P; Codega, P; Cupelli, L; Cupri, A; De Risi, C; Di Renzo, N; Federico, V; Guarini, A; Matera, R; Mazza, P; Mengarelli, A; Messa, AR; Musso, M; Pastore, D; Perrone, T; Scimè, R; Seripa, D; Specchia, G, 2022
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiemeticA drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
delta-lactamA lactam in which the amide bond is contained within a six-membered ring, which includes the amide nitrogen and the carbonyl carbon.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
azabicycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3BHomo sapiens (human)IC50 (µMol)0.00090.00041.95059.0000AID1056939
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)IC50 (µMol)50.11870.12004.048010.0000AID1207381
5-hydroxytryptamine receptor 3AHomo sapiens (human)IC50 (µMol)0.00300.00011.07899.0000AID1056939; AID1056941; AID1056943; AID1056944; AID1056946; AID1056948; AID1056949; AID1056950; AID1056951; AID1784770
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki0.00000.00000.74119.9000AID537659
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)IC50 (µMol)50.11870.12004.048010.0000AID1207381
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)2.98820.00091.901410.0000AID1207475; AID1207535
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)398.10700.00032.25459.6000AID1207569
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)19.95260.00033.64849.2000AID1207321
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3BHomo sapiens (human)Kd0.00030.00000.01370.1060AID1056974; AID1056975; AID1056976; AID1056977; AID1056978; AID1056990
5-hydroxytryptamine receptor 3AHomo sapiens (human)Kd0.00040.00000.00980.1060AID1056978; AID1056980; AID1056981; AID1056982; AID1056983; AID1056984; AID1056985; AID1056987; AID1056988; AID1056989; AID1056991
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (115)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
epithelial cell maturationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
male gonad developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
vestibular nucleus developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
secretory granule organizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to acidic pHPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to light stimulusPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of protein targeting to membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
gastrin-induced gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
glucose metabolic processPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
heart developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
rhythmic behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of blood pressurePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of heart ratePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
iodide transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
erythrocyte differentiationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intracellular chloride ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
response to insulinPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
social behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
corticosterone secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intestinal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
auditory receptor cell developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
stomach developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal sodium ion absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to epinephrine stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
adrenergic receptor signaling pathwayPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cochlea developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
non-motile cilium assemblyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium channel regulator activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
telethonin bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein-containing complex bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein phosphatase 1 bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A catalytic subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A regulatory subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
late endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transport vesiclePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmic vesicle membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuron projectionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ciliary basePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lumenal side of membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral part of cellPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
monoatomic ion channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID1056945Antagonist activity at human 5-HT3A receptor F130Y mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056942Antagonist activity at human 5-HT3A receptor D165A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056976Binding affinity to human 5-HT3B receptor W90C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056991Binding affinity to human wild type 5-HT3A receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID552110Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells at 3 uM relative to 5HT2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
AID1056978Binding affinity to human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056947Antagonist activity at human 5-HT3A receptor W90C mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1207321Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1207441Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID1056973Binding affinity to human 5-HT3B receptor E170A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056933Antagonist activity at human 5-HT3B receptor I183A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056950Antagonist activity at human 5-HT3A receptor Y73A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056935Antagonist activity at human 5-HT3B receptor Y143A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056989Binding affinity to human 5-HT3A receptor Y73A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056937Antagonist activity at human 5-HT3B receptor W90C mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056951Antagonist activity at human wild type 5-HT3A receptor expressed in HEK293 cells assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056986Binding affinity to human 5-HT3A receptor W90C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056938Antagonist activity at human 5-HT3B receptor H73A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1207381Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056934Antagonist activity at human 5-HT3B receptor E170A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056984Binding affinity to human 5-HT3A receptor F130Y mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056979Binding affinity to human 5-HT3A receptor W183C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056941Antagonist activity at human 5-HT3A receptor D165K mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056985Binding affinity to human 5-HT3A receptor F130A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1207475Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID1056975Binding affinity to human 5-HT3B receptor F130A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056931Displacement of [3H]-quipazine from 5-HT3 receptor in mouse/rat NG108-15 cells2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1056949Antagonist activity at human 5-HT3A receptor Y73F mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1207569Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID537659Binding affinity to 5HT3A receptor2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
AID1056932Ratio of IC50 for human 5-HT3A receptor Y73A mutant to IC50 for human wild type 5-HT3A receptor2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056983Binding affinity to human 5-HT3A receptor S163A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056946Antagonist activity at human 5-HT3A receptor F130A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1207535Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056987Binding affinity to human 5-HT3A receptor Y73S mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056988Binding affinity to human 5-HT3A receptor Y73F mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID537660Chemical stability of the compound assessed as half life2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
AID1056972Ratio of Kd for human 5-HT3B receptor F130A mutant to Kd for human wild type 5-HT3A/5-HT3B receptor2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056980Binding affinity to human 5-HT3A receptor D165K mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056940Antagonist activity at human 5-HT3A receptor W183C mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056944Antagonist activity at human 5-HT3A receptor S163A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056943Antagonist activity at human 5-HT3A receptor S163T mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID552297Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as decrease in 100 uM 5-chloroindole-induced increase in intracellular calcium release at 3 uM relative to 5-HT2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
AID1056974Binding affinity to human 5-HT3B receptor Y143A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056952Ratio of Kd for human 5-HT3A receptor Y73A mutant to Kd for human wild type 5-HT3A receptor2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056948Antagonist activity at human 5-HT3A receptor Y73S mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1784770Antagonist activity at human 5-HT3 receptor expressed in CHO-K1 cells assessed as inhibition of 5-HT induced inward currents preincubated for 30 sec followed by 5HT addition for 2 sec at -60 mV holding potential by ion flux automated patch clamp assay
AID1056981Binding affinity to human 5-HT3A receptor D165A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056982Binding affinity to human 5-HT3A receptor S163T mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056939Antagonist activity at human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056990Binding affinity to human 5-HT3B receptor I183A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056977Binding affinity to human 5-HT3B receptor H73A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056936Antagonist activity at human 5-HT3B receptor F130A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (446)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (0.90)18.2507
2000's78 (17.49)29.6817
2010's290 (65.02)24.3611
2020's74 (16.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.45 (24.57)
Research Supply Index6.50 (2.92)
Research Growth Index6.19 (4.65)
Search Engine Demand Index130.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials197 (42.00%)5.53%
Reviews92 (19.62%)6.00%
Case Studies6 (1.28%)4.05%
Observational15 (3.20%)0.25%
Other159 (33.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (110)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial [NCT03578081]Phase 3690 participants (Actual)Interventional2018-10-15Completed
A Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen Prior to Hematopoietic Cell Transplantation (HSCT) [NCT03097588]Phase 243 participants (Actual)Interventional2017-04-27Completed
Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery [NCT01169805]105 participants (Actual)Interventional2010-08-31Completed
A Randomized, Double Blind, Multicenter Phase III Trial to Evaluate the Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting [NCT01568268]Phase 3384 participants (Actual)Interventional2012-01-31Completed
Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery [NCT04853147]Phase 31,154 participants (Actual)Interventional2021-04-27Completed
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy [NCT01370408]Phase 285 participants (Actual)Interventional2012-02-29Completed
MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial [NCT02135510]Phase 3249 participants (Actual)Interventional2013-06-30Completed
One Day Antiemetic Prophylaxis of NEPA (Netupitant Plus Palonosetron) and Dexamethasone to Prevent Chemotherapy-induced Nausea and Vomiting (CINV) in Breast Cancer Patients Receiving an AC-based Chemotherapy Regimen [NCT03862144]Phase 2150 participants (Actual)Interventional2016-05-12Completed
Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting: a Phase III, Double-blind, Randomized, Placebo-controlled Trial in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting [NCT01088022]Phase 3120 participants (Anticipated)Interventional2010-04-30Not yet recruiting
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial [NCT05841849]Phase 41,028 participants (Anticipated)Interventional2023-07-31Not yet recruiting
Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy [NCT02445872]Phase 280 participants (Anticipated)Interventional2015-12-31Not yet recruiting
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer [NCT04308837]Phase 229 participants (Anticipated)Interventional2018-12-03Recruiting
The Efficacy and Safety of Thalidomide in Preventing Multi-cycle, Cisplatin-containing CINV: a Pragmatic Randomized Open-label Clinical Trial [NCT03601871]880 participants (Anticipated)Interventional2018-07-12Recruiting
Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy [NCT02205164]Phase 2134 participants (Anticipated)Interventional2011-10-31Recruiting
The Optimization of Antiemetic Regimen for Chemoradiotherapy-induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCCs): A Prospective Phase Ⅱ Trial [NCT05202275]Phase 243 participants (Anticipated)Interventional2020-12-01Recruiting
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. [NCT03606369]Phase 2/Phase 3560 participants (Anticipated)Interventional2015-11-05Recruiting
Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care: A Randomized Controlled Phase II Feasibility Trial [NCT05315999]Phase 230 participants (Anticipated)Interventional2022-05-03Recruiting
Olanzapine for the Prevention of Delayed Nausea and Vomiting in Patients With Gynecologic Cancers Receiving Carboplatin and Paclitaxel-based Chemotherapy and Guideline-directed Prophylactic Anti-emetics [NCT02290470]Phase 281 participants (Anticipated)Interventional2014-04-30Recruiting
Comparison of Palonosetron With Combined Palonosetron and Midazolam for Preventing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy [NCT03933605]88 participants (Actual)Interventional2017-07-10Completed
A Multicenter Multinational Randomized Double Blind PK/PD Dose-finding Study of Oral Netupitant Given With Oral Palonosetron in Pediatric Cancer Patients for Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy [NCT03204279]Phase 267 participants (Actual)Interventional2017-08-31Completed
Efficacy and Safety of Palonosetron HCl Buccal Film Versus IV Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy [NCT05199818]Phase 3328 participants (Anticipated)Interventional2022-03-01Recruiting
Prospective, Double-blind Study Comparing Palonosetron and Dexamethasone in the Prophylaxis of Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery [NCT04060771]Phase 380 participants (Anticipated)Interventional2018-08-01Recruiting
A Multi-Center, Open-Label, 2-Arm, Randomized, Stratified, Parallel, Pilot Study to Assess Palonosetron vs. Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU) [NCT00967499]Phase 2239 participants (Actual)Interventional2009-07-13Completed
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin. [NCT01074697]Phase 3246 participants (Actual)Interventional2010-04-30Completed
Drug Disposition and Nephrotoxicity [NCT03817970]Phase 372 participants (Anticipated)Interventional2019-11-15Recruiting
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial [NCT02203253]Phase 3642 participants (Actual)Interventional2014-07-31Completed
Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy [NCT02541019]Phase 480 participants (Actual)Interventional2015-10-31Completed
[NCT02744508]202 participants (Actual)Interventional2015-07-24Completed
Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers [NCT02650479]Phase 182 participants (Actual)Interventional2016-01-31Completed
A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients [NCT00666783]Phase 2208 participants (Actual)InterventionalCompleted
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study [NCT04201769]Phase 3261 participants (Actual)Interventional2016-11-25Active, not recruiting
Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy [NCT02532634]Phase 4292 participants (Actual)Interventional2015-08-19Completed
Phase II Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy [NCT01018758]Phase 286 participants (Actual)Interventional2006-07-31Completed
Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study [NCT00600353]Phase 220 participants (Actual)Interventional2007-10-31Completed
A Comparison Between Palonosetron And Ondansetron As Prophylaxis Against Postoperative Nausea and Vomiting In Idiopathic Scoliosis Surgery: A Randomised Trial [NCT05956899]Phase 474 participants (Anticipated)Interventional2023-06-01Recruiting
Open-label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomit (CINV). [NCT00687011]Phase 4118 participants (Actual)Interventional2006-10-10Completed
Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia [NCT00684463]Phase 459 participants (Actual)Interventional2007-04-11Completed
A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation [NCT00895245]Phase 26 participants (Actual)Interventional2009-02-28Terminated(stopped due to Study stopped due to lack of efficacy in first 6 patients)
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients [NCT03040726]Phase 2/Phase 353 participants (Actual)Interventional2017-05-03Completed
Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy. [NCT03960151]Phase 20 participants (Actual)Interventional2018-05-31Withdrawn(stopped due to Compound was sold by funder and development ceased.)
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous (SC) Versus Intravenous Palonosetron in Cancer Patients Treated With Platinum Based Chemotherapy [NCT01046240]Phase 1/Phase 229 participants (Actual)Interventional2009-10-31Completed
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy [NCT01909856]Phase 292 participants (Actual)Interventional2011-10-31Completed
Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron [NCT01952626]80 participants (Actual)Interventional2013-04-30Completed
A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg (ALOXI®) for the Prevention of Chemotherapy-induced Nausea and [NCT04592198]Phase 222 participants (Actual)Interventional2020-10-01Completed
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Palonosetron After Intravenous Administration of Palonosetron in Healthy Volunteers Under Fasting Conditions [NCT04585412]Phase 416 participants (Actual)Interventional2020-08-17Completed
Comparison of Palonosetron and Ondansetron for the Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery [NCT04533867]100 participants (Actual)Observational [Patient Registry]2020-08-15Completed
A Comparative Study Between Palonosetron vs the Combination of Granisetron and Dexamethasone in Preventing Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy. [NCT06043336]Phase 4134 participants (Actual)Interventional2018-05-10Completed
The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of Postoperative Nausea and Vomiting in the Women Patients Undergoing Thyroidectomy [NCT02809378]Phase 4150 participants (Actual)Interventional2016-06-30Completed
Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide [NCT00900757]Phase 257 participants (Actual)Interventional2009-08-31Completed
Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy [NCT05509634]Phase 3754 participants (Actual)Interventional2022-09-21Completed
Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing Endoscopic Retrograde Cholangio-Pancreatography ERCP: A Prospective Randomized Controlled Study [NCT04576390]Phase 490 participants (Anticipated)Interventional2020-10-24Not yet recruiting
Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation [NCT01872494]Phase 471 participants (Actual)Interventional2013-05-31Completed
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting [NCT00903396]Phase 27 participants (Actual)Interventional2009-09-30Terminated(stopped due to Slow accrual)
Effect of Continuous Infusion of Palonosetron Following Single Prophylactic Injection of Palonosetron for Preventing Postoperative Nausea and Vomiting [NCT01482468]132 participants (Anticipated)Interventional2012-03-31Recruiting
Comparative Study Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients Undergoing Breast Surgery [NCT02941913]Phase 480 participants (Actual)Interventional2016-10-31Completed
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients:a Randomized Phase 3 Trial [NCT02933099]Phase 3300 participants (Anticipated)Interventional2016-10-31Not yet recruiting
MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study [NCT04817189]Phase 4530 participants (Anticipated)Interventional2021-02-01Recruiting
COMPARATIVE STUDY BETWEEN PALONOSETRON AND FOSAPREPITANT IN THE PROFILAXIA OF POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN SUBMITTED TO VIDEOLAPAROSCOPIC COLECISTECTOMIES [NCT03586817]Phase 4100 participants (Anticipated)Interventional2019-03-02Recruiting
A Randomized Double Blind Study to Evaluate Efficacy of Ramosetron and Palonosetron for Prevention of Postoperative Nausea and Vomiting After Gynaecological Laparoscopic Surgery [NCT01476280]100 participants (Actual)Interventional2011-05-31Completed
Comparative Study of TIVA(Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing PONV(Postoperative Nausea and Vomiting) [NCT01478165]100 participants (Actual)Interventional2011-09-30Completed
A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China [NCT01481831]Phase 4599 participants (Actual)Interventional2011-07-31Completed
A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles. [NCT03649230]207 participants (Actual)Observational2018-10-03Completed
A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population [NCT00503386]Phase 2144 participants (Actual)Interventional2006-04-30Completed
Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study [NCT00661674]10 participants (Actual)Interventional2008-04-30Completed
A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexame [NCT01339260]Phase 31,455 participants (Actual)Interventional2011-04-30Completed
Effect of Palonosetron on Effect-site Concentration of Remifentanil for Preventing Emergence Cough During General Anesthesia in Female Patients Undergoing Laparoscopic Cholecystectomy [NCT04563260]45 participants (Actual)Interventional2020-10-07Completed
Fixed Dose Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory Chemotherapy-Induced Nausea and Vomiting [NCT03008213]Phase 24 participants (Actual)Interventional2017-01-31Terminated(stopped due to PI is leaving UCSD)
Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting [NCT02970643]48 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
The Effect of a Palonosetron on Blood Coagulation: In Vitro, Volunteer Study Using Thromboelastography [NCT04507711]12 participants (Anticipated)Interventional2020-09-16Recruiting
Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy [NCT00553059]Phase 362 participants (Actual)Interventional2008-05-31Completed
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial [NCT00475085]Phase 31,021 participants (Actual)Interventional2006-12-31Completed
A Phase II Single Arm Trial of Palonosetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan in Combination With Bevacizumab [NCT00636805]Phase 263 participants (Actual)Interventional2008-05-31Terminated(stopped due to Study was halted early after 63 subjects were enrolled due to slow accrual.)
A Multicenter, Double-blind, Randomized, Parallel Group, Stratified Study to Assess the Safety and Efficacy of Single IV Doses of Palonosetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients [NCT00828295]Phase 3150 participants (Actual)Interventional2008-08-31Completed
Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia [NCT02635828]Phase 440 participants (Actual)Interventional2009-10-31Completed
Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC). [NCT01640340]40 participants (Actual)Interventional2011-01-31Completed
Treatment of Refractory Nausea [NCT03367572]Phase 31,600 participants (Anticipated)Interventional2018-04-19Recruiting
AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nause [NCT00415103]Phase 4196 participants (Anticipated)Interventional2006-11-30Completed
A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation [NCT00306735]Phase 275 participants (Anticipated)Interventional2006-03-31Completed
The Effect of Palonosetron on the QTc Interval During Perioperative Period [NCT01650961]100 participants (Actual)Interventional2012-07-31Completed
[NCT01825733]196 participants (Actual)Interventional2011-08-31Completed
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP. [NCT01843868]130 participants (Anticipated)Interventional2013-05-31Not yet recruiting
A Phase 3, Single-dose, Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron 0.25 mg Administered as a 30-minute IV Infusion Compared to Palonosetron 0.25 mg Administered as a 30-second IV Bolus for [NCT02557035]Phase 3441 participants (Actual)Interventional2015-10-31Completed
A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemothera [NCT02517021]Phase 3405 participants (Actual)Interventional2015-11-30Completed
Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant [NCT02597907]88 participants (Actual)Interventional2014-07-31Completed
Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy [NCT00412425]Phase 1/Phase 230 participants (Actual)Interventional2006-11-30Completed
UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients [NCT00982995]Phase 23 participants (Actual)Interventional2010-11-30Terminated(stopped due to site terminated due to lack of enrollment)
Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy [NCT00359567]Phase 31,140 participants (Anticipated)Interventional2006-07-31Completed
Randomized Double Blind Study to Evaluate the Efficacy of IV Palo w/ IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed Post-Operative Nausea/Vomiting in Subj Undergoing Laparoscopic Surgeries w/a High Emetogenic Risk [NCT00952133]Phase 4118 participants (Actual)Interventional2009-07-31Completed
Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy- [NCT01363479]Phase 3743 participants (Actual)Interventional2011-07-31Completed
Comparison of the Effects of Palonosetron + Dexamethazone, Ondansetron + Dexamethazone and Dexametazone Alone Against Postoperative Nausea and Vomiting in Pediatric Patients Undergoing Laparoscopic Surgery [NCT05439798]Phase 366 participants (Anticipated)Interventional2022-06-01Enrolling by invitation
Palonosetron Hydrochloride Capsules (Ruoshan ®) Used to Prevent and Control Chemotherapy for Tumor Patients Real World Study on the Safety of Nausea and Vomiting Reduction [NCT05690802]1,060 participants (Anticipated)Interventional2022-05-16Recruiting
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]27,034 participants (Actual)Interventional2016-07-31Completed
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial [NCT02116530]Phase 3401 participants (Actual)Interventional2014-08-31Completed
Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial [NCT03674294]Phase 3248 participants (Actual)Interventional2015-08-04Completed
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupita [NCT03403712]Phase 3404 participants (Actual)Interventional2018-03-16Completed
Prospective Study of Palonosetron in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting (RINV) - a Phase II Study [NCT02388750]Phase 296 participants (Actual)Interventional2015-04-30Completed
Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients [NCT00343863]41 participants (Actual)Interventional2006-01-31Completed
Intensive Medicines Monitoring Project of Palonosetron Hydrochloride Capsules [NCT03148704]3,000 participants (Anticipated)Observational2017-03-08Recruiting
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma [NCT06102447]36 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Ped [NCT01395901]Phase 3670 participants (Actual)Interventional2011-06-30Completed
A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderate [NCT00343460]Phase 31,428 participants (Actual)Interventional2006-06-30Completed
Phase II, Open, Randomized Comparative Trial of Two Different Schedules of Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting in Patients With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine [NCT01031498]Phase 2150 participants (Actual)Interventional2005-09-30Completed
Dose/Schedule Finding Study of Palonosetron in Sarcoma Patients Receiving Multi-Day Chemotherapy With Adriamycin and Ifosfamide (AI) [NCT00410488]51 participants (Actual)Interventional2006-12-31Completed
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX [NCT00381862]Phase 254 participants (Actual)Interventional2006-06-30Completed
Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting: a Phase 3 Non-inferiority Randomized Trial [NCT04912271]Phase 3140 participants (Anticipated)Interventional2021-06-10Not yet recruiting
A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy [NCT01376297]Phase 3413 participants (Actual)Interventional2011-07-31Completed
[NCT02480088]Phase 4300 participants (Actual)Interventional2014-09-22Completed
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC o [NCT01442376]Phase 3502 participants (Actual)Interventional2011-09-30Completed
Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia: Study Single Center, Prospective, Double-blind, Randomized, Placebo Controlled [NCT02468323]Phase 4150 participants (Actual)Interventional2015-10-31Completed
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial [NCT02484911]Phase 3120 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00343460 (11) [back to overview]Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1
NCT00343460 (11) [back to overview]First and Overall Use of Rescue Medication
NCT00343460 (11) [back to overview]Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses
NCT00343460 (11) [back to overview]Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1
NCT00343460 (11) [back to overview]Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1
NCT00343460 (11) [back to overview]Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1
NCT00343460 (11) [back to overview]Time to First Treatment Failure
NCT00343460 (11) [back to overview]Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)
NCT00343460 (11) [back to overview]Quality of Life and the Impact of Nausea and Vomiting on Day 5
NCT00343460 (11) [back to overview]Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1
NCT00343460 (11) [back to overview]Number of Emetic Episodes
NCT00343863 (8) [back to overview]Count of Patients Achieving a Complete Response
NCT00343863 (8) [back to overview]Severity of Nausea
NCT00343863 (8) [back to overview]Count of Patients Achieving Complete Response
NCT00343863 (8) [back to overview]Number of Days With Emetic Episodes and Rescue Medicines
NCT00343863 (8) [back to overview]Side Effects of Antiemetic Medications Used
NCT00343863 (8) [back to overview]Quality of Life
NCT00343863 (8) [back to overview]Number of Participants That Had Emesis Within 48 Hours of Chemotherapy
NCT00343863 (8) [back to overview]Number of Participants That Had First Administration of Rescue Medication Within 48 Hours
NCT00381862 (1) [back to overview]Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.
NCT00410488 (1) [back to overview]Palonosetron Response Rate in the 10 Day Study Cycle
NCT00412425 (1) [back to overview]Cumulative Participants Response to Palonosetron
NCT00475085 (1) [back to overview]Home Record: Severity of Delayed Nausea
NCT00553059 (7) [back to overview]Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Nausea for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Total Protection in the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Vomiting for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants Received Rescue Medication in the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Complete Protection for the Acute, Delayed, and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Complete Response for the Acute, Delayed, and Overall Periods
NCT00600353 (4) [back to overview]Overall Emetic Response: Delayed
NCT00600353 (4) [back to overview]Overall Emetic Response: Acute
NCT00600353 (4) [back to overview]Overall Emetic Response
NCT00600353 (4) [back to overview]Overall Emetic Response: Extended
NCT00636805 (7) [back to overview]Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate
NCT00636805 (7) [back to overview]Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy
NCT00636805 (7) [back to overview]Percentage of Patients With ≥ Grade 3, Treatment-related Toxicities
NCT00636805 (7) [back to overview]Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Anticoagulant Use at Baseline
NCT00636805 (7) [back to overview]Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Corticosteroid Use at Baseline
NCT00636805 (7) [back to overview]Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy by Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR)
NCT00636805 (7) [back to overview]Acute CINV (Chemotherapy Induced Nausea and Vomiting) CR (Complete Response) Rate
NCT00661674 (2) [back to overview]OOWS Score
NCT00661674 (2) [back to overview]SOWS Score
NCT00828295 (2) [back to overview]Proportion of Patients With Complete Response 0-24 Hours
NCT00828295 (2) [back to overview]Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively
NCT00895245 (4) [back to overview]Rate of Complete Response to Anti-emetic Therapy in the Delayed Setting (25-120 Hours After Cisplatin Infusion)
NCT00895245 (4) [back to overview]Proportion of Patients With a Complete Response to the Anti-emetic Medication Regimen
NCT00895245 (4) [back to overview]Control of Nausea for 120 Hours Following Each Cisplatin Infusion for Multiple Cycles of Therapy as Measured by the Visual Analog Scale
NCT00895245 (4) [back to overview]Impact of Cisplatin-induced Nausea and Vomiting on Daily Life During the 5 Day Period Following Cisplatin Infusion for Multiple Cycles as Measured by the Functional Living Index-Emesis Questionnaire
NCT00900757 (5) [back to overview]Percentage of Participants With a Osoba Nausea Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)
NCT00900757 (5) [back to overview]Percentage of Participants With a Osoba Vomiting/Retching Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)
NCT00900757 (5) [back to overview]Change in the Functional Living Index - Emesis (FLIE) Score From Baseline to Each Week of Radiation (XRT) and Temozolomide (TMZ) Treatment
NCT00900757 (5) [back to overview]Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity
NCT00900757 (5) [back to overview]Complete Response
NCT00952133 (2) [back to overview]Complete Response Rate
NCT00952133 (2) [back to overview]Number of Participants Who Experienced no or Reduced Post-Operative Nausea Vomiting (PONV) the First 96 Hours After Surgery
NCT00967499 (6) [back to overview]Modified Osoba Nausea and Emesis Module Questionnaire Score
NCT00967499 (6) [back to overview]Change From Baseline in Nausea Severity Score
NCT00967499 (6) [back to overview]Percentage of Participants With Complete Response
NCT00967499 (6) [back to overview]Percentage of Participants Who Did Not Experience Any Episode of Emesis
NCT00967499 (6) [back to overview]Percentage of Participants Who Did Not Receive Any Rescue Medication Post-surgical Procedure
NCT00967499 (6) [back to overview]Percentage of Participants With Complete Control
NCT01031498 (1) [back to overview]Number of Patients With Complete Response
NCT01339260 (3) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication at Cycle 1
NCT01339260 (3) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1
NCT01339260 (3) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1
NCT01363479 (3) [back to overview]Percentage of Patients With no Rescue Medication
NCT01363479 (3) [back to overview]Percentage of Patients With no Emesis
NCT01363479 (3) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication
NCT01370408 (8) [back to overview]Number of Patients That Experience Treatment Failure Within the First 24 Hours
NCT01370408 (8) [back to overview]Complete Control Rate for Nausea & Vomiting
NCT01370408 (8) [back to overview]Complete Remission During Acute Phase Post-chemotherapy
NCT01370408 (8) [back to overview]Complete Remission During Overall Chemotherapy Time Period
NCT01370408 (8) [back to overview]Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting
NCT01370408 (8) [back to overview]Emetic Episodes
NCT01370408 (8) [back to overview]Number of Patients That Required First Administration of Rescue Medication Within 24 Hours
NCT01370408 (8) [back to overview]Patients Who Experience First Emetic Episode Within 24 Hours
NCT01376297 (1) [back to overview]Percentage of Patients With Adverse Events
NCT01395901 (5) [back to overview]Proportion of Patients With no Vomiting
NCT01395901 (5) [back to overview]Proportion of Patients Without Nausea (Patient Aged > 6 Years)
NCT01395901 (5) [back to overview]Proportion of Patients Without Emetic Episodes
NCT01395901 (5) [back to overview]Proportion of Patients Without Antiemetic Rescue Medication
NCT01395901 (5) [back to overview]Proportion of Patients With Complete Response
NCT01442376 (2) [back to overview]Proportion of Patients With Complete Response >24 to 120 Hours (Delayed Phase) in Cycle 1
NCT01442376 (2) [back to overview]Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1
NCT01640340 (6) [back to overview]Delayed CR (Complete Response)
NCT01640340 (6) [back to overview]Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication
NCT01640340 (6) [back to overview]Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours
NCT01640340 (6) [back to overview]Use of Rescue Medication for Each Treatment Arm
NCT01640340 (6) [back to overview]Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours
NCT01640340 (6) [back to overview]Acute CR (Complete Response)
NCT02116530 (5) [back to overview]Frequency of Rescue Medication
NCT02116530 (5) [back to overview]Proportion of Patients With no Nausea
NCT02116530 (5) [back to overview]Proportion of Patients With Complete Response
NCT02116530 (5) [back to overview]Median Nausea Scores
NCT02116530 (5) [back to overview]Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With Complete Response in Overall Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With Complete Response in the Acute Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With Complete Response in Overall Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With Complete Response in the Acute Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase
NCT02484911 (12) [back to overview]Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase
NCT02517021 (10) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase
NCT02517021 (10) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase
NCT02517021 (10) [back to overview]Percentage of Patients With no Emetic Episodes in the Acute Phase
NCT02517021 (10) [back to overview]Percentage of Patients With no Emetic Episodes in the Delayed Phase
NCT02517021 (10) [back to overview]Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Acute Phase
NCT02517021 (10) [back to overview]Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Delayed Phase
NCT02517021 (10) [back to overview]Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Overall Phase
NCT02517021 (10) [back to overview]Percentage of Patients With Adverse Events
NCT02517021 (10) [back to overview]Percentage of Patients With no Emetic Episodes in the Overall Phase
NCT02517021 (10) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Emetic Episodes in the Acute Phase
NCT02557035 (9) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase
NCT02557035 (9) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase
NCT02557035 (9) [back to overview]Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Rescue Medication in the Overall Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Rescue Medication in the Delayed Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Rescue Medication in the Acute Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Emetic Episodes in the Overall Phase
NCT02557035 (9) [back to overview]Percentage of Patients With no Emetic Episodes in the Delayed Phase
NCT02597907 (1) [back to overview]The Incidence of Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02635828 (2) [back to overview]PONV Incidence
NCT02635828 (2) [back to overview]Incidence of Subjects Significant QTc Changes in the EKG
NCT03008213 (1) [back to overview]Number of Participants Completed All Study Procedures Over Seven Days
NCT03040726 (4) [back to overview]Functional Living Index Emesis (FLIE): Vomiting Sub-score
NCT03040726 (4) [back to overview]Index of Nausea, Vomiting and Retching: Total Experience Score
NCT03040726 (4) [back to overview]Functional Living Index Emesis (FLIE): Nausea Sub-score
NCT03040726 (4) [back to overview]Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15
NCT03097588 (11) [back to overview]Complete Response (CR) Defined as no Emesis and no Rescue Therapy
NCT03097588 (11) [back to overview]Complete Protection (CP) Rate Defined as CR Plus no Nausea
NCT03097588 (11) [back to overview]Time to Receiving First Rescue Medication and First Emesis
NCT03097588 (11) [back to overview]Time to First Emesis and Time to Receiving First Rescue Medication
NCT03097588 (11) [back to overview]Number of Participants With Emetic Episodes and Received Rescue Agents (Delayed Phase)
NCT03097588 (11) [back to overview]Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)
NCT03097588 (11) [back to overview]Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)
NCT03097588 (11) [back to overview]Number of Participants With Emetic Episodes and Received Rescue Agents
NCT03097588 (11) [back to overview]Mean Levels of Nausea Per Day Assessed by Chemotherapy Induced Nausea and Vomiting Questionnaire
NCT03097588 (11) [back to overview]CR (Delayed Phase)
NCT03097588 (11) [back to overview]CR (Acute Phase)
NCT03204279 (5) [back to overview]Maximum Plasma Concentration (Cmax) of Netupitant
NCT03204279 (5) [back to overview]Maximum Plasma Concentration (Cmax) of Netupitant
NCT03204279 (5) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant
NCT03204279 (5) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant
NCT03204279 (5) [back to overview]Percentage of Pediatric Patients With Complete Response During the Delayed Phase
NCT03403712 (8) [back to overview]Number of Participants With Treatment-emergent AEs at Cycle 1
NCT03403712 (8) [back to overview]Complete Response in Cycle 1 During the Overall Phase
NCT03403712 (8) [back to overview]Complete Response in Cycle 1 During the Delayed Phase
NCT03403712 (8) [back to overview]Complete Response in Cycle 1 During the Acute Phase
NCT03403712 (8) [back to overview]Number of Participants With Study-Drug-Related TEAEs Reported for ≥2% of Patients in Either Treatment Group Throughout the Study
NCT03403712 (8) [back to overview]Number of Participants With Severe (i.e., CTCAE Grade ≥3) TEAEs Reported for ≥2% of Patients in Either Treatment Group and Overall Throughout the Study
NCT03403712 (8) [back to overview]Number of Participants With Treatment-emergent AEs All Cycles
NCT03403712 (8) [back to overview]Overall Percentage of Patients With NIDL Based on FLIE Scores for Cycles 1
NCT03578081 (5) [back to overview]Average Nausea Scores (0-10) Repeatedly Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]Total Frequency of Rescue Medication as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]Potential Toxicities as Ascribed to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and Delayed (24-120 Hours) Periods
NCT03578081 (5) [back to overview]Complete Response (CR) (no Emetic Episodes and no Use of Rescue Medication) During the Acute, Delayed and the Overall Periods as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03649230 (2) [back to overview]Total Functional Living Index-Emesis (FLIE) Score at Cycle 1
NCT03649230 (2) [back to overview]Severity of Nausea on Day 5 (Change From Day 1)

Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1

Complete control is defined as complete response with no more than mild nausea. (NCT00343460)
Timeframe: 0-120 Hours

,,,,,
Interventionparticipants (Number)
CC during acute PhaseCC during the delayed-onset phaseCC during the overall risk period
Cycle 1 Aloxi 0.25 Highly184147136
Cycle 1 Aloxi 0.25 mg - Moderately14710799
Cycle 1 APF530 10 mg - Highly183150138
Cycle 1 APF530 10 mg - Moderately152115107
Cycle 1 APF530 5 mg - Highly170138127
Cycle 1 APF530 5 mg - Moderately15410093

[back to top]

First and Overall Use of Rescue Medication

(NCT00343460)
Timeframe: 0-120 Hours

,,,,,
Interventionparticipants (Number)
Used Rescue Medication, 0-24 hoursUsed Rescue Medication, 24-120 hoursUsed Rescue Medication, 0-120 hours
Cycle 1 Aloxi 0.25 - Highly254249
Cycle 1 Aloxi 0.25 mg - Moderately416372
Cycle 1 APF530 10 mg - Highly234245
Cycle 1 APF530 10 mg - Moderately376976
Cycle 1 APF530 5 mg - Highly356071
Cycle 1 APF530 5 mg - Moderately428389

[back to top]

Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses

"Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles~Complete Response is defined as no emetic episodes and no use of rescue medications" (NCT00343460)
Timeframe: 0-120 Hours

Interventionparticipants with overall CR (Number)
Cycles 1, 2, 3 and 4 - Moderately34
Cycles 1, 2, 3, and 4 - Moderately35
Cycles 1, 2, 3 and 4 - Highly56
Cycles 1, 2, 3, and 4 - Highly52

[back to top]

Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1

Complete Response is defined as no emetic episodes and no use of rescue medications (NCT00343460)
Timeframe: 24-120 Hours

Interventionparticipants (Number)
Cycle 1 APF530 5 mg - Moderately110
Cycle 1 APF530 10 mg - Moderately125
Cycle 1 Aloxi 0.25 mg - Moderately120
Cycle 1 APF530 5 mg - Highly148
Cycle 1 APF530 10 mg - Highly164
Cycle 1 Aloxi 0.25 Highly158

[back to top]

Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1

Complete Response is defined as no emetic episodes and no use of rescue medications (NCT00343460)
Timeframe: 0-24 Hours

Interventionparticipants (Number)
Cycle 1 APF530 5 mg - Moderately160
Cycle 1 APF530 10 mg - Moderately163
Cycle 1 Aloxi 0.25 mg - Moderately156
Cycle 1 APF530 5 mg - Highly178
Cycle 1 APF530 10 mg - Highly195
Cycle 1 Aloxi 0.25 Highly192

[back to top]

Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1

Subject who were very satisfied on Day 1 (NCT00343460)
Timeframe: 0- 24 Hours

Interventionparticipants (Number)
Cycle 1 APF530 5 mg - Moderately101
Cycle 1 APF530 10 mg - Moderately113
Cycle 1 Aloxi 0.25 mg - Moderately98
Cycle 1 APF530 5 mg - Highly128
Cycle 1 APF530 10 mg - Highly128
Cycle 1 Aloxi 0.25 - Highly135

[back to top]

Time to First Treatment Failure

Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration (NCT00343460)
Timeframe: 0-120 Hours

,,,,,
InterventionProportion of subjects event free (Number)
24 Hours48 Hours72 Hours96 Hours120 Hours
Cycle 1 Aloxi 0.25 - Highly0.8030.7140.6720.6340.620
Cycle 1 Aloxi 0.25 mg - Moderately0.7550.6350.5670.5340.529
Cycle 1 APF530 10 mg - Highly0.8110.7230.6850.6680.647
Cycle 1 APF530 10 mg - Moderately0.7630.6590.5640.5500.540
Cycle 1 APF530 5 mg - Highly0.7810.7060.6490.6180.600
Cycle 1 APF530 5 mg - Moderately0.7380.6360.5330.4850.485

[back to top]

Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)

Maximum severity of nausea, days 1-5 (NCT00343460)
Timeframe: 0-120 Hours

,,,,,
Interventionparticipants (Number)
NoneMildModerateSevere
Cycle 1 Aloxi 0.25 - Highly121533919
Cycle 1 Aloxi 0.25 mg - Moderately66684624
Cycle 1 APF530 10 mg - Highly102683728
Cycle 1 APF530 10 mg - Moderately85534032
Cycle 1 APF530 5 mg - Highly105534813
Cycle 1 APF530 5 mg - Moderately78455930

[back to top]

Quality of Life and the Impact of Nausea and Vomiting on Day 5

Functional Living Index (NCT00343460)
Timeframe: 5 days

,,,,,
Interventionparticipants (Number)
No nausea impact on daily lifeNo vomiting impact on daily life
Cycle 1 Aloxi 0.25 - Highly159191
Cycle 1 Aloxi 0.25 mg - Moderately120160
Cycle 1 APF530 10 mg - Highly142182
Cycle 1 APF530 10 mg - Moderately127162
Cycle 1 APF530 5 mg - Highly142173
Cycle 1 APF530 5 mg - Moderately112157

[back to top]

Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1

"TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1.~TR during delayed-onset phase is defined as Complete Response with no nausea during >24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1." (NCT00343460)
Timeframe: 0-120 Hours

,,,,,
Interventionparticipants (Number)
TR during acute phaseTR during the delayed-onset phaseTR during the overall risk period
Cycle 1 Aloxi 0.25 Highly158122117
Cycle 1 Aloxi 0.25 mg - Moderately1137365
Cycle 1 APF530 10 mg - Highly146113101
Cycle 1 APF530 10 mg - Moderately1218979
Cycle 1 APF530 5 mg - Highly141115103
Cycle 1 APF530 5 mg - Moderately1357668

[back to top]

Number of Emetic Episodes

Number of Emetic Episodes - days 1-5 (NCT00343460)
Timeframe: Days 1-5

InterventionNumber of Emetic Episodes (Mean)
Cycle 1 APF530 5 mg - Moderately3.4
Cycle 1 APF530 10 mg - Moderately3.1
Cycle 1 Aloxi 0.25 mg - Moderately2.1
Cycle 1 APF530 5 mg - Highly2.3
Cycle 1 APF530 10 mg - Highly2.4
Cycle 1 Aloxi 0.25 Highly2.5

[back to top]

Count of Patients Achieving a Complete Response

(NCT00343863)
Timeframe: At 0-24 hours after weekly intravenous doxorubin

InterventionParticipants (Count of Participants)
Dexamethasone + Ondansetron IV3
Dexamethasone + Palonosetron IV15

[back to top]

Severity of Nausea

Count of participants with severe nausea (NCT00343863)
Timeframe: Up to 3 months

InterventionParticipants (Count of Participants)
Dexamethasone + Ondansetron IV1
Dexamethasone + Palonosetron IV4

[back to top]

Count of Patients Achieving Complete Response

(NCT00343863)
Timeframe: At 24-120 hours after weekly intravenous doxorubicin

InterventionParticipants (Count of Participants)
Dexamethasone + Ondansetron IV3
Dexamethasone + Palonosetron IV15

[back to top]

Number of Days With Emetic Episodes and Rescue Medicines

(NCT00343863)
Timeframe: Up to 3 months

,
Interventiondays (Median)
Vomiting during neoadjuvant chemotherapyTook rescue medicines
Dexamethasone + Ondansetron IV02
Dexamethasone + Palonosetron IV09.5

[back to top]

Side Effects of Antiemetic Medications Used

(NCT00343863)
Timeframe: Up to 3 months

,
InterventionParticipants (Count of Participants)
ConstipationHeadaches
Dexamethasone + Ondansetron IV20
Dexamethasone + Palonosetron IV152

[back to top]

Quality of Life

(NCT00343863)
Timeframe: Up to 3 months

InterventionFLIE questionnaires (Count of Units)
FLIE Nausea72045916FLIE Nausea72045917FLIE Vomiting72045916FLIE Vomiting72045917
High impact (<36)Medium impact (36-54)No impact of daily life (>54)
Dexamethasone + Ondansetron IV4
Dexamethasone + Palonosetron IV44
Dexamethasone + Ondansetron IV5
Dexamethasone + Palonosetron IV74
Dexamethasone + Ondansetron IV26
Dexamethasone + Palonosetron IV248
Dexamethasone + Ondansetron IV1
Dexamethasone + Palonosetron IV10
Dexamethasone + Ondansetron IV3
Dexamethasone + Palonosetron IV9
Dexamethasone + Ondansetron IV31
Dexamethasone + Palonosetron IV347

[back to top]

Number of Participants That Had Emesis Within 48 Hours of Chemotherapy

Count of patients that had emesis within 48 hours of chemotherapy (NCT00343863)
Timeframe: Up to 48 hours of chemotherapy

InterventionParticipants (Count of Participants)
Dexamethasone + Ondansetron IV0
Dexamethasone + Palonosetron IV1

[back to top]

Number of Participants That Had First Administration of Rescue Medication Within 48 Hours

Count of patients that had first administration of rescue medication within 48 Hours (NCT00343863)
Timeframe: up to 48 hours of chemotherapy

InterventionParticipants (Count of Participants)
Dexamethasone + Ondansetron IV1
Dexamethasone + Palonosetron IV4

[back to top]

Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.

(NCT00381862)
Timeframe: Up to 24 weeks

InterventionParticipants (Number)
Aprepitant and Palonosetron54

[back to top]

Palonosetron Response Rate in the 10 Day Study Cycle

Number of participants with dose of palonosetron who experienced response (no emesis) during acute and delayed time period of the study (10 days) divided by number of participants. Complete response defined as no emesis and no rescue medicines in 10 days from the start of chemotherapy in the first chemotherapy cycle. (NCT00410488)
Timeframe: 10 days

Interventionpercentage of participants (Number)
Palonosetron - 1 Dose31.25
Palonosetron - 3 Doses50

[back to top]

Cumulative Participants Response to Palonosetron

Participants response measured as incidences biochemotherapy emesis and those of nausea interfering with appetite, sleep, physical activity, social life and enjoyment of life are summarized. Response evaluated during 5-day administration of biochemotherapy and the 23 subsequent days after therapy ends. (NCT00412425)
Timeframe: 7 days

,
Interventionepisodes of nausea/vomiting (Number)
Nausea Episodes (First 7 days)Vomiting Episodes (First 7 days)
2 Days Palonosetron13972
3 Days Palonosetron8544

[back to top]

Home Record: Severity of Delayed Nausea

1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse (NCT00475085)
Timeframe: average of day 1 afternoon, evening and night, and all of days 2 and 3

Interventionunits on a scale (Mean)
Arm II1.88
Arm III1.65
Arm I1.87
Arm IV1.68

[back to top]

Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods

Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol4715
Placebo2810

[back to top]

Number of Participants With Nausea for the Acute, Delayed and Overall Periods

Number of Participants with Nausea for the Acute, Delayed and Overall Periods. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol81911
Placebo15235

[back to top]

Number of Participants With Total Protection in the Acute, Delayed and Overall Periods

Total protection is defined as no vomiting, no rescue therapy, and no nausea as indicated by responses to the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. Data to be recorded in the study diary during the 5-day study period. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221111
Placebo1455

[back to top]

Number of Participants With Vomiting for the Acute, Delayed and Overall Periods

Number of Participants with Vomiting Acute, Delayed and Overall. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol61019
Placebo3919

[back to top]

Number of Participants Received Rescue Medication in the Acute, Delayed and Overall Periods

The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. The first section asks the patient to record presence and severity of nausea during the last 24 hours. The second section asks the patient to record vomiting episodes during the last 24 hours. The third section asks if the patient took medication for nausea or vomiting during the last 24 hours and asks how useful the treatment for nausea or vomiting was. The fourth section screens for toxicity by asking about side effects and problems experienced during the last 24 hours. Use of rescue antiemetic medication and adverse events also assessed and documented. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedResponse
Dronabinol31110
Placebo51512

[back to top]

Number of Participants With Complete Protection for the Acute, Delayed, and Overall Periods

Complete Protection is no vomiting, no rescue therapy, and no nausea evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: Up to 5 days (first 5 days following first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221414
Placebo18109

[back to top]

Number of Participants With Complete Response for the Acute, Delayed, and Overall Periods

Complete response is defined as vomiting episodes with rescue medication evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: Up to 5 days (first 5 days following first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221415
Placebo191312

[back to top]

Overall Emetic Response: Delayed

"Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.~Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.~Failure - >5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5." (NCT00600353)
Timeframe: 24 to 72 hours after chemotherapy

,
InterventionParticipants (Count of Participants)
CCCRMRFailureNSN
Group A - Subjects With Multiple Myeloma216000
Group B - Subjects With Relpased Lymphoma405008

[back to top]

Overall Emetic Response: Acute

"Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.~Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.~Failure - >5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5." (NCT00600353)
Timeframe: 24 hours after chemotherapy

,
InterventionParticipants (Count of Participants)
CCCRMRFailureNSN
Group A - Subjects With Multiple Myeloma513009
Group B - Subjects With Relpased Lymphoma900009

[back to top]

Overall Emetic Response

Clinical responses were summarized using frequencies and percentages by phase, disease group, and overall. To compute emetic response by phase, the previously defined criteria were applied to each day of the three phases independently. The worst response was used to represent the response in each of these phases and overall emetic response. Overall emetic response was computed by applying the same definitions of emetic response to the entire study period. (NCT00600353)
Timeframe: At leaset 24 hours to more than 72 hours after chemotherapy

,
InterventionParticipants (Count of Participants)
CCCRMRFailureNSN
Group A - Subjects With Multiple Myeloma008106
Group B - Subjects With Relpased Lymphoma106205

[back to top]

Overall Emetic Response: Extended

"Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.~Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.~Failure - >5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5." (NCT00600353)
Timeframe: 72 hours after chemotherapy

,
InterventionParticipants (Count of Participants)
CCCRMRFailureNSN
Group A - Subjects With Multiple Myeloma107000
Group B - Subjects With Relpased Lymphoma207005

[back to top]

Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate

Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) complete response (CR) rate is defined as the percentage of patients who do not have an emetic episode or use antiemetic rescue medication during days 2 through 5 of chemotherapy treatment during the first cycle of treatment (NCT00636805)
Timeframe: Days 2-5 of the first week of chemotherapy

Interventionpercentage of participants (Number)
Patient Receives IV Aloxi62

[back to top]

Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy

Overall mean change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score from baseline to day 5 of the first week of chemotherapy. The FACIT-Fatigue is a 13-item validated questionnaire assessing the impact of fatigue on an individual's quality of life. The raw score range is 0-52 with higher scores indicating better quality of life. The mean change from baseline to day 5 was calculated by subtracting the baseline score from mean of the day 1-5 scores, thus a negative mean change represents worsening in quality of life due to fatigue. (NCT00636805)
Timeframe: Baseline through day 5 of the first week of chemotherapy

Interventionunits on a scale (Mean)
Patient Receives IV Aloxi-3.5

[back to top] [back to top]

Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Anticoagulant Use at Baseline

Acute Chemotherapy-Induced Nausea and Vomiting (CINV) complete response (CR) rate is defined as the percentage of patients who do not have an emetic episode or use antiemetic rescue medication during the first 24 hours following chemotherapy of the first cycle of treatment. (NCT00636805)
Timeframe: Day 1 of the first week of chemotherapy

Interventionpercentage of participants (Number)
anticoagulant used at baselineno anticoagulant used at baseline
Patient Receives IV Aloxi6163

[back to top]

Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Corticosteroid Use at Baseline

Acute Chemotherapy-Induced Nausea and Vomiting (CINV) complete response (CR) rate is defined as the percentage of patients who do not have an emetic episode or use antiemetic rescue medication during the first 24 hours following chemotherapy of the first cycle of treatment. (NCT00636805)
Timeframe: Day 1 of the first week of chemotherapy

Interventionpercentage of participants (Number)
corticosteroid used at baselineno corticosteroid used at baseline
Patient Receives IV Aloxi6858

[back to top]

Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy by Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR)

Overall mean change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score from baseline to day 5 of the first week of chemotherapy. The FACIT-Fatigue is a 13-item validated questionnaire assessing the impact of fatigue on an individual's quality of life. The raw score range is 0-52 with higher scores indicating better quality of life. The mean change from baseline to day 5 was calculated by subtracting the baseline score from the mean of the day 1-5 scores, thus a negative mean change represents worsening in quality of life due to fatigue. Acute CINV complete response (CR) is defined as not having an emetic episode or any use of antiemetic rescue medication during the first 24 hours following chemotherapy of the first cycle of treatment. (NCT00636805)
Timeframe: Baseline through day 5 of the first week of chemotherapy

Interventionunits on a scale (Mean)
CRNot CR
Patient Receives IV Aloxi-3.5-3.3

[back to top]

Acute CINV (Chemotherapy Induced Nausea and Vomiting) CR (Complete Response) Rate

Acute Chemotherapy-Induced Nausea and Vomiting (CINV) complete response (CR) rate is defined as the percentage of patients who do not have an emetic episode or use antiemetic rescue medication during the first 24 hours following chemotherapy of the first cycle of treatment. (NCT00636805)
Timeframe: first 24 hours of the first week of chemotherapy

Interventionpercentage of participants (Number)
Patient Receives IV Aloxi62

[back to top]

OOWS Score

"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)

Interventionunits on a scale (OOWS Scale) (Mean)
Placebo3.5
Palonosetron1.0
Palonosetron + Hydroxyzine0

[back to top]

SOWS Score

"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)

Interventionunits on a scale (SOWS Scale) (Mean)
Placebo6.0
Palonosetron4.0
Palonosetron + Hydroxyzine3.5

[back to top]

Proportion of Patients With Complete Response 0-24 Hours

Complete Response defined as no vomiting, no retching, and no use of rescue medication (NCT00828295)
Timeframe: 0-24 hours

Interventionpercentage of patients (Number)
1 mcg/kg Arm88.0
3 mcg/kg Arm84.0

[back to top]

Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively

(NCT00828295)
Timeframe: 0-72 hours post-operatively

Interventionpercentage of patients (Number)
1 mcg/kg Arm88.0
3 mcg/kg Arm84.0

[back to top]

Rate of Complete Response to Anti-emetic Therapy in the Delayed Setting (25-120 Hours After Cisplatin Infusion)

(NCT00895245)
Timeframe: 25-120 hours following cisplatin infusion

InterventionParticipants (Count of Participants)
Arm I0

[back to top]

Proportion of Patients With a Complete Response to the Anti-emetic Medication Regimen

Complete response is defined as no emesis or rescue nausea medications needed in the first 120 hours following cisplatin infusion. (NCT00895245)
Timeframe: 120 hours following cisplatin infusion

InterventionParticipants (Count of Participants)
Arm I0

[back to top]

Control of Nausea for 120 Hours Following Each Cisplatin Infusion for Multiple Cycles of Therapy as Measured by the Visual Analog Scale

"The visual analog scale ranges from 0-100. 0 is labeled as no nausea and 100 is labeled as nausea as bad as it could be A score of < 25 is considered to indicate no significant nausea. All patients discontinued trial after only one cisplatin infusion." (NCT00895245)
Timeframe: 120 hours following cisplatin infusion

Interventionmillimeters (Mean)
Arm I45.2

[back to top]

Impact of Cisplatin-induced Nausea and Vomiting on Daily Life During the 5 Day Period Following Cisplatin Infusion for Multiple Cycles as Measured by the Functional Living Index-Emesis Questionnaire

"FLIE is a patient-completed quality of life assessment modified from the original Functional Living Index - Cancer questionnaire. FLIE contains two domains: nausea and vomiting with nine items in each domain. The first item asks the patient to rate how much nausea (or vomiting) has occurred over a 5 day period. The remaining eight items ask patients to rate the impact of nausea (or vomiting) on various aspects of a patient's life (for example, ability to enjoy meals/liquids). Each item is answered using a 7 point visual analog scale with 7 being none /not at all and 1 being a great deal. The two domains are summed for a total score with a possible range of 18-126. Higher scores indicate a more favorable quality of life. A total score of >108 defines those patients who had a minimal impact of CINV on quality of life. All particpants discontinued the trial after one cycle of cisplatin." (NCT00895245)
Timeframe: 5 days following cisplatin infusion

Interventionunits on a scale (Mean)
Arm I83.98

[back to top]

Percentage of Participants With a Osoba Nausea Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)

Percentage of participants with a Osoba nausea module maximum standardized score of zero for each week of radiation (XRT) and Temozolomide (TMZ). The Osoba nausea module is a 5-item questionnaire assessing the effect of nausea on quality of life and daily functioning. Raw scores range from 5-20 and have been converted to standardized scores (0-100) using the formula: std_score = round((raw_score - 5) * 6.66). Lower scores indicate better quality fo life. The maximum standardized score of all nausea scores collected during the week (days 1, 3 and 6) was used for this outcome. (NCT00900757)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Week 1 of XRT and TMZ (n=38)Week 2 of XRT and TMZ (n=38)Week 3 of XRT and TMZ (n=38)Week 4 of XRT and TMZ (n=38)Week 5 of XRT and TMZ (n=35)Week 6 of XRT and TMZ (n=34)
Palonosetron767979797179

[back to top]

Percentage of Participants With a Osoba Vomiting/Retching Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)

Percentage of participants with a Osoba vomiting/retching module maximum standardized score of zero for each week of radiation (XRT) and Temozolomide (TMZ). The Osoba vomiting/retching module is a 5-item questionnaire assessing the effect of vomiting/retching on quality of life and daily functioning. Raw scores range from 5-20 and have been converted to standardized scores (0-100) using the formula: std_score = round((raw_score - 5) * 6.66). Lower scores indicate better quality fo life. The maximum standardized score of all vomiting/retching scores collected during the week (days 1, 3 and 6) was used for this outcome. (NCT00900757)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Week 1 of XRT and TMZ (n=38)Week 2 of XRT and TMZ (n=38)Week 3 of XRT and TMZ (n=38)Week 4 of XRT and TMZ (n=38)Week 5 of XRT and TMZ (n=35)Week 6 of XRT and TMZ (n=34)
Palonosetron8789100928997

[back to top]

Change in the Functional Living Index - Emesis (FLIE) Score From Baseline to Each Week of Radiation (XRT) and Temozolomide (TMZ) Treatment

The FLIE is a 18-item validated questionnaire for assessing the effects of chemotherapy-induced nausea and emesis on quality of life and daily functioning. The raw score range is 18-126 with higher scores indicating better quality of life. For each week of XRT and TMZ, the change from baseline was calculated by subtracting the baseline score from the mean of the day 1, 3 and 6 scores. A negative change represents worsening in quality of life due to nausea and emesis. (NCT00900757)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Week 1 of XRT and TMZ (n=38)Week 2 of XRT and TMZ (n=38)Week 3 of XRT and TMZ (n=38)Week 4 of XRT and TMZ (n=38)Week 5 of XRT and TMZ (n=36)Week 6 of XRT and TMZ (n=34)
Palonosetron-3.3-2.7-1.9-3.9-5.5-4.1

[back to top]

Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity

The number of participants with unacceptable toxicity defined as ≥grade 3, non-hematologic toxicities that are possibly, probably or definitely related to the study regimen. (NCT00900757)
Timeframe: 6 weeks

Interventionparticipants (Number)
Palonosetron5

[back to top]

Complete Response

The percentage of participants with a complete response defined as no emetic episode or use of rescue medication while receiving radiation (XRT) and concomitant temozolomide (TMZ). (NCT00900757)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Week 1 of XRT and TMZ (n=38)Week 2 of XRT and TMZ (n=38)Week 3 of XRT and TMZ (n=38)Week 4 of XRT and TMZ (n=38)Week 5 of XRT and TMZ (n=36)Week 6 of XRT and TMZ (n=34)Overall (across weeks 1-6 of XRT and TMZ) (N=34)
Palonosetron74797674677144

[back to top]

Complete Response Rate

A Complete Response (CR): defined as no nausea, no vomiting/retching, no rescue medication and no withdrawal of consent from the time of administration of the study drug(s) until 72 hours post emergence from anesthesia. (NCT00952133)
Timeframe: Pre-op through 72 hours post emergence from anesthesia

,
Interventionparticipants (Number)
0-2 Hours - no rescue medication0-6 Hours - no rescue medication0-72 Hours - no rescue medication
Palonosetron Only383226
Palonosetron With Dexamethasone383232

[back to top]

Number of Participants Who Experienced no or Reduced Post-Operative Nausea Vomiting (PONV) the First 96 Hours After Surgery

Participants with no or reduced post operative nausea over a 96 hour period after surgery. questionnaires answered after surgery at 2 hour, 6 hour, 12 hour 72 hour and 96 hours post surgery. (NCT00952133)
Timeframe: Pre-op through 96 hours post-op

Interventionparticipants (Number)
Dexamethasone32
Placebo26

[back to top]

Modified Osoba Nausea and Emesis Module Questionnaire Score

"Modified Osoba nausea and emesis module questionnaire was used to assess the impact of nausea and emesis on functional interference at 24, 48 and 72 hours postdose. The modified Osoba questionnaire included specific questions regarding the interference of nausea and emesis in daily activities (appetite, sleep, physical activities, social life, and enjoyment of life) with respective choices. The raw score of the modified Osoba questionnaire was the arithmetic mean of the non-missing item scores, using 1 for the answer not at all, 2 for the answer a little, 3 for the answer quite a bit, and 4 for the answer very much. Raw score range from 5-20 and the total score was computed by linearly transformed the raw score to final score range as 0 to 100 by calculating ([RS-1]/range)*100, with RS being the raw score and range being 3 in this case of answers scored from 1 to 4. Lower scores indicate better quality of life." (NCT00967499)
Timeframe: 24, 48 and 72 hours postdose

,
Interventionscore on a scale (Mean)
24 Hours Postdose48 Hours Postdose72 Hours Postdose
Ondansetron12.17.06.2
Palonosetron11.36.56.7

[back to top]

Change From Baseline in Nausea Severity Score

Severity of nausea was assessed at specific time points using an 11-point NRS scale (ranging from 0-10) for evaluation of nausea severity. On the 0-10 rating scale, 0 means no nausea, 2 or 3 was mild nausea, around 5 was moderate nausea, 7 and higher was severe nausea and 10 means the worst possible nausea. Higher scores were considered as worse outcome. (NCT00967499)
Timeframe: Baseline up to 72 hours postdose

,
Interventionscore on a scale (Mean)
BaselineChange at 72 hours postdose
Ondansetron5.9-5.6
Palonosetron5.7-5.1

[back to top]

Percentage of Participants With Complete Response

Complete response was defined as participants with no emetic episode and no use of rescue medication. An emetic episodic is defined as any number of retches (unproductive emesis) in a single 5-minute period; 1 or a sequence of vomits in a close succession not relieved by a period of relaxation of at least 2 minutes; or retching of less than (<) 5 minutes duration combined with a single vomit. (NCT00967499)
Timeframe: Up to 72 hours postdose

Interventionpercentage of participants (Number)
Palonosetron31.3
Ondansetron26.0

[back to top]

Percentage of Participants Who Did Not Experience Any Episode of Emesis

(NCT00967499)
Timeframe: Up to 72 hours postdose

Interventionpercentage of participants (Number)
Palonosetron70.8
Ondansetron52.0

[back to top]

Percentage of Participants Who Did Not Receive Any Rescue Medication Post-surgical Procedure

(NCT00967499)
Timeframe: Up to 72 hours postdose

Interventionpercentage of participants (Number)
Palonosetron37.5
Ondansetron44.0

[back to top]

Percentage of Participants With Complete Control

Complete control was defined as participants with no emetic episode, no rescue medication, and no more than 3 on the nausea numeric rating scale (NRS) severity score. The 11-point NRS scale (ranging from 0-10), where 0 means no nausea, 2 or 3 was mild nausea, around 5 was moderate nausea, 7 and higher was severe nausea and 10 means the worst possible nausea. Higher scores were considered as worse outcome. (NCT00967499)
Timeframe: Up to 72 hours postdose

Interventionpercentage of participants (Number)
Palonosetron25.0
Ondansetron18.0

[back to top]

Number of Patients With Complete Response

Number of emesis (vomiting) episodes and no use of rescue medication during the administration of chemotherapy assessed as complete response. Complete response is defined as < or equal to 1 episode of emesis during entire 7-day study period, no use of of rescue medication during the study period, and no more than moderate nausea (Grade 2, National Cancer Institutes (NCI) Common Terminology Criteria (CTC)) during chemotherapy. (NCT01031498)
Timeframe: 7 days, starting first day of chemotherapy

Interventionparticipants (Number)
Ondansetron: Standard of Care11
Palonosetron Group 1 (5 Days)15
Palonosetron Group 2 (3 Days)18

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication at Cycle 1

(NCT01339260)
Timeframe: 0-24 hours

Interventionpercentage of responders (Number)
Netupitant and Palonosetron Plus Dexamethasone88.4
Palonosetron Plus Dexamethasone85.0

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1

(NCT01339260)
Timeframe: 0-120 hours

Interventionpercentage of responders (Number)
Netupitant and Palonosetron Plus Dexamethasone74.3
Palonosetron Plus Dexamethasone66.6

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1

(NCT01339260)
Timeframe: 25-120 hours

Interventionpercentage of responders (Number)
Netupitant and Palonosetron Plus Dexamethasone76.9
Palonosetron Plus Dexamethasone69.5

[back to top]

Percentage of Patients With no Rescue Medication

(NCT01363479)
Timeframe: 0-24 hours

Interventionpercentage of responders (Number)
Oral Palonosteron Plus Dexamethasone94.6
I.V. Palonosetron Plus Dexamethasone93.2

[back to top]

Percentage of Patients With no Emesis

(NCT01363479)
Timeframe: 0-24 hours

Interventionpercentage of responders (Number)
Oral Palonosteron Plus Dexamethasone90.2
I.V. Palonosetron Plus Dexamethasone86.7

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication

(NCT01363479)
Timeframe: 0-24 hours

Interventionpercentage of responders (Number)
Oral Palonosteron Plus Dexamethasone89.4
I.V. Palonosetron Plus Dexamethasone86.2

[back to top]

Number of Patients That Experience Treatment Failure Within the First 24 Hours

Number of patients with first emetic episode or time to administration of rescue therapy, whichever occurred first, within the first 24 hours (NCT01370408)
Timeframe: 24 hours

Interventionparticipants (Number)
Palonosetron49

[back to top]

Complete Control Rate for Nausea & Vomiting

Complete control rate (CC; defined as no emetic episodes, no rescue medication use, and no more than mild nausea) (NCT01370408)
Timeframe: 120 hours

Interventionparticipants (Number)
Palonosetron8

[back to top]

Complete Remission During Acute Phase Post-chemotherapy

Proportion of patients achieving an acute CINV CR during the acute phase post -chemotherapy (0-24 hours) (NCT01370408)
Timeframe: 24 hours

Interventionparticipants (Number)
Palonosetron33

[back to top]

Complete Remission During Overall Chemotherapy Time Period

Proportion of patients achieving a CR during the cumulative overall 0-120 hour time period (NCT01370408)
Timeframe: 120 hours

Interventionparticipants (Number)
Palonosetron10

[back to top]

Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting

Proportion of patients achieving a delayed CINV complete response (CR) defined as no emetic episode and no use of rescue medications during the 24-120 hour period post chemotherapy. (NCT01370408)
Timeframe: 120 hours

Interventionparticipants (Number)
Palonosetron13

[back to top]

Emetic Episodes

Number of emetic episodes (NCT01370408)
Timeframe: 120 Hours

Interventionepisodes (Mean)
Palonosetron1.7

[back to top]

Number of Patients That Required First Administration of Rescue Medication Within 24 Hours

Number of patients who required the use of rescue medication (lorazepam, prochlorperazine, promethazine, metoclopramide, scopolamine, or dronabinol) within the first 24 hours (NCT01370408)
Timeframe: 24 hours

Interventionparticipants (Number)
Palonosetron46

[back to top]

Patients Who Experience First Emetic Episode Within 24 Hours

Number of patients with first emetic episode experienced within 24 hours (NCT01370408)
Timeframe: 24 hours

Interventionparticipants (Number)
Palonosetron15

[back to top]

Percentage of Patients With Adverse Events

This was a safety study where Adverse Events is the primary outcome (defined by the current ICH Guideline for Good Clinical Practice). Patients were randomized according to a 3:1 ratio (netupitant/palonosetron:aprepitant/palonosetron). No formal comparison was planned, the presence of a control in the same patient population helped interpret any unexpected safety finding in the experimental arm.The number of patients was estimated in order to have more than 100 patients treated with the netupitant/palonosetron comination for up to at least six cycles. Based on 100 patients, if a given AE is not observed, an AE incidence of 3% or greater can be excluded with 95% confidence. (NCT01376297)
Timeframe: Participants will be followed for the duration of the chemotherapy, an expected average duration of up to 24 weeks assuming 6 chemotherapy cycles given every 4 weeks

Interventionpercentage of patients with TEAE (Number)
Netupitant and Palonosetron Plus Dexamethasone86.0
Aprepitant and Palonosetron Plus Dexamethasone91.3

[back to top]

Proportion of Patients With no Vomiting

Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively. (NCT01395901)
Timeframe: 0-24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron and Placebo to Ondansetron83.1
Ondansetron and Placebo to Palonosetron87.6

[back to top]

Proportion of Patients Without Nausea (Patient Aged > 6 Years)

(NCT01395901)
Timeframe: 0-24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron and Placebo to Ondansetron83.2
Ondansetron and Placebo to Palonosetron82.0

[back to top]

Proportion of Patients Without Emetic Episodes

An emetic episode was defined as one or more continuous vomits (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively. (NCT01395901)
Timeframe: 0-24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron and Placebo to Ondansetron80.1
Ondansetron and Placebo to Palonosetron83.9

[back to top]

Proportion of Patients Without Antiemetic Rescue Medication

Rescue medications are any medications with potential antiemetic effect taken in the 24 hours after patient wake-up from anaesthesia (T0).Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively. (NCT01395901)
Timeframe: 0-24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron and Placebo to Ondansetron93.1
Ondansetron and Placebo to Palonosetron96.4

[back to top]

Proportion of Patients With Complete Response

Complete Response was defined as no vomiting, no retching, and no use of antiemetic rescue medication during the first 24 hours postoperatively, starting at T0. Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively. (NCT01395901)
Timeframe: 0-24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron and Placebo to Ondansetron78.2
Ondansetron and Placebo to Palonosetron82.7

[back to top]

Proportion of Patients With Complete Response >24 to 120 Hours (Delayed Phase) in Cycle 1

Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from >24 to 120 hours (delayed phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. (NCT01442376)
Timeframe: from >24 to 120 hours (delayed phase) after T0

Interventionpercentage of patients (Number)
Palonosetron 10 mcg/kg28.9
Palonosetron 20 mcg/kg38.8
Ondansetron28.4

[back to top]

Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1

Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. Time 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy. (NCT01442376)
Timeframe: 0 to 24 hours after T0

Interventionpercentage of patients (Number)
Palonosetron 10 mcg/kg54.2
Palonosetron 20 mcg/kg59.4
Ondansetron58.6

[back to top]

Delayed CR (Complete Response)

After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication From Time 24to 120 Hours. (NCT01640340)
Timeframe: 24-120 hours after chemotherapy

Interventionpercentage of participants (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)65
Arm B (Ondansetron 24 mg Oral on Day 1)45

[back to top]

Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication

We will use exact binomial methods to estimate proportions and their associated 95% confidence intervals. (NCT01640340)
Timeframe: Up to 120 hours after completion of chemotherapy

Interventionpercentage of patients (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)65
Arm B (Ondansetron 24 mg Oral on Day 1)40

[back to top]

Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours

The percentage of patients who experienced grade 1, 2 or 3 vomiting from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE v 4.0 vomiting Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated. (NCT01640340)
Timeframe: From time 0 to 120 hours

Interventionpercentage of participants (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)5
Arm B (Ondansetron 24 mg Oral on Day 1)15

[back to top]

Use of Rescue Medication for Each Treatment Arm

(NCT01640340)
Timeframe: From time 0 to 120 hours

Interventionpercentage of participants (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)35
Arm B (Ondansetron 24 mg Oral on Day 1)55

[back to top]

Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours

The percentage of patients who experienced grade 1, 2 or 3 nausea from time 0 to 120 hours. Nausea graded using the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects)version 4.0 Nausea Grading Scale. Grade 1=Loss of appetite without alteration in eating habits, Grade 2= Oral intake decreased without significant weight loss, dehydration or malnutrition, Grade 3= Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated. (NCT01640340)
Timeframe: Time 0 to 120 hours

Interventionpercentage of participants (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)55
Arm B (Ondansetron 24 mg Oral on Day 1)65

[back to top]

Acute CR (Complete Response)

After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication from time 0 to 24 hours. (NCT01640340)
Timeframe: 0-24 hours after chemotherapy

Interventionpercentage of particpants (Number)
Arm A (Palonosetron 0.25 mg IV on Day 1)75
Arm B (Ondansetron 24 mg Oral on Day 1)55

[back to top]

Frequency of Rescue Medication

Patients were asked to record daily number of extra nausea/vomiting pills taken because they developed nausea/vomiting in the following categories: None, One, Two, More than two in Nausea and Vomiting Daily Diary Questionnaire. (NCT02116530)
Timeframe: Day 2 to Day 6 after chemotherapy

InterventionParticipants (Count of Participants)
Day 272213840Day 272213839Day 372213839Day 372213840Day 472213839Day 472213840Day 572213840Day 572213839Day 672213839Day 672213840
More than twiceTwiceNoneOnce
Olanzapine156
Placebo117
Olanzapine21
Placebo35
Placebo19
Olanzapine2
Olanzapine158
Placebo124
Olanzapine11
Placebo24
Olanzapine7
Placebo20
Olanzapine4
Placebo10
Olanzapine141
Olanzapine16
Olanzapine10
Placebo17
Olanzapine3
Placebo11
Olanzapine145
Placebo131
Olanzapine19
Placebo23
Olanzapine5
Placebo7
Olanzapine143
Placebo130
Olanzapine12
Placebo16
Placebo14

[back to top]

Proportion of Patients With no Nausea

No nausea was defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire in the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods after chemotherapy. (NCT02116530)
Timeframe: 0 to 120 hours after chemotherapy

,
Interventionpercentage of participants (Number)
0-24 hours after chemotherapy25-120 hours after chemotherapy0-120 hours after chemotherapy
Olanzapine73.842.437.3
Placebo45.325.421.9

[back to top]

Proportion of Patients With Complete Response

Complete response was defined as no emetic episodes and no use of rescue medication during the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods as measured by the Nausea and Vomiting Daily Diary/Questionnaire. (NCT02116530)
Timeframe: 0 to 120 hours after chemotherapy

,
Interventionpercentage of participants (Number)
0-24 hours after chemotherapy25-120 hours after chemotherapy0-120 hours after chemotherapy
Olanzapine85.766.963.6
Placebo64.652.440.6

[back to top]

Median Nausea Scores

Nausea scores was measured using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be). (NCT02116530)
Timeframe: Baseline and Day 2 to Day 6 after chemotherapy

,
Interventionunits on a scale (Median)
BaselineDay 2Day 3Day 4Day 5Day 6
Olanzapine000000
Placebo011111

[back to top] [back to top]

Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase

"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen30
Control Regimen30

[back to top]

Proportion of Participants Receiving HEC With Complete Response in Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Control Regimen15

[back to top]

Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase

"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen30
Control Regimen31

[back to top]

Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase

"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue )" (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen18
Control Regimen15

[back to top]

Proportion of Participants Receiving HEC With Complete Response in the Acute Phase

Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Control Regimen17

[back to top]

Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase

"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen20
Aprepitant Regimen15

[back to top]

Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase

"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen17
Control Regimen7

[back to top]

Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen17
Control Regimen6

[back to top]

Proportion of Participants Receiving MEC With Complete Response in Overall Phase

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen40

[back to top]

Proportion of Participants Receiving MEC With Complete Response in the Acute Phase

Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen41

[back to top]

Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase

"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen36
Control Regimen40

[back to top]

Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase

"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours

InterventionParticipants (Count of Participants)
Olanzapine Regimen35
Control Regimen40

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase

(NCT02517021)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone159
Netupitant/Palonosetron Plus Dexamethasone176

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase

(NCT02517021)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone156
Netupitant/Palonosetron Plus Dexamethasone169

[back to top]

Percentage of Patients With no Emetic Episodes in the Acute Phase

(NCT02517021)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone164
Netupitant/Palonosetron Plus Dexamethasone165

[back to top]

Percentage of Patients With no Emetic Episodes in the Delayed Phase

(NCT02517021)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone173
Netupitant/Palonosetron Plus Dexamethasone184

[back to top]

Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Acute Phase

(NCT02517021)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone183
Netupitant/Palonosetron Plus Dexamethasone187

[back to top]

Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Delayed Phase

(NCT02517021)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone165
Netupitant/Palonosetron Plus Dexamethasone179

[back to top]

Percentage of Patients With no Significant Nausea (VAS <25 mm) During the Overall Phase

(NCT02517021)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone161
Netupitant/Palonosetron Plus Dexamethasone174

[back to top]

Percentage of Patients With Adverse Events

This is a safety study where Adverse Events is the primary outcome (defined by the current ICH Guideline for Good Clinical Practice). Patients are randomized according to a 1:1 ratio (IV NEPA FDC : oral NEPA FDC). No formal comparison is planned, the presence of a control in the same patient population helps interpret any unexpected safety finding in the experimental arm. It is expected that the number of patients randomized to the test group, i.e., 200, will allow approximately 100 patients to be treated with the test drug for 4 cycles. Based on 100 patients treated at Cycle 4 with the IV NEPA FDC , if a given Adverse Event (AE) is not observed, an AE incidence of 3% or greater can be excluded with 95% confidence. (NCT02517021)
Timeframe: Participants will be followed for the duration of the chemotherapy, an expected average duration of up to 14 weeks assuming a maximum of 4 chemotherapy cycles given every 3 weeks.

,
InterventionParticipants (Count of Participants)
Any TEAESevere TEAESerious TEAETEAE leading to deathTEAE leading to discontinuation from the study
Netupitant/Palonosetron Plus Dexamethasone17490431420
Pro-netupitant/Palonosetron Plus Dexamethasone16986411016

[back to top]

Percentage of Patients With no Emetic Episodes in the Overall Phase

(NCT02517021)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone171
Netupitant/Palonosetron Plus Dexamethasone178

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase

(NCT02517021)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
Pro-netupitant/Palonosetron Plus Dexamethasone188
Netupitant/Palonosetron Plus Dexamethasone182

[back to top]

Percentage of Patients With no Emetic Episodes in the Acute Phase

(NCT02557035)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone186
I.V. Palonosetron Bolus Plus Dexamethasone190

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase

(NCT02557035)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone150
I.V. Palonosetron Bolus Plus Dexamethasone156

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase

(NCT02557035)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone170
I.V. Palonosetron Bolus Plus Dexamethasone165

[back to top]

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase

(NCT02557035)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone186
I.V. Palonosetron Bolus Plus Dexamethasone186

[back to top]

Percentage of Patients With no Rescue Medication in the Overall Phase

(NCT02557035)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone173
I.V. Palonosetron Bolus Plus Dexamethasone169

[back to top]

Percentage of Patients With no Rescue Medication in the Delayed Phase

(NCT02557035)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone183
I.V. Palonosetron Bolus Plus Dexamethasone176

[back to top]

Percentage of Patients With no Rescue Medication in the Acute Phase

(NCT02557035)
Timeframe: 0-24 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone200
I.V. Palonosetron Bolus Plus Dexamethasone195

[back to top]

Percentage of Patients With no Emetic Episodes in the Overall Phase

(NCT02557035)
Timeframe: 0-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone155
I.V. Palonosetron Bolus Plus Dexamethasone160

[back to top]

Percentage of Patients With no Emetic Episodes in the Delayed Phase

(NCT02557035)
Timeframe: >24-120 hours

InterventionParticipants (Count of Participants)
I.V. Palonosetron Infusion Plus Dexamethasone176
I.V. Palonosetron Bolus Plus Dexamethasone168

[back to top]

The Incidence of Postoperative Nausea and Vomiting

The incidence of postoperative nausea and vomiting during 24 hours postoperatively (NCT02597907)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Aprepitant Plus Palonosetron5
Aprepitant Plus Ramosetron18

[back to top]

Adherence to PONV Guidelines

PONV guideline adherence: percentage of patients who received the exact number of prophylactic interventions for PONV that were recommended by the decision support. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: the start of admission at the holding room to the end of the anesthetic case

InterventionParticipants (Count of Participants)
Baseline Measurement666
CDS Email Recommendations5260
CDS Email + Real TIme Recommenations5863

[back to top]

The Number of Prophylactic Interventions for PONV

the absolute number of prophylactic interventions applied between the admission of the patient in the holding room until admission to the PACU. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission at the holding room to the end of the anesthetic case

Interventionprophylactic antiemetics administered (Mean)
Baseline Measurement2.196
CDS Email Recommendations2.176
CDS Email + Real TIme Recommenations2.129

[back to top]

PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting

The occurrence of PONV, as defined by the administration of antiemetics in the PACU between admission to PACU and discharge from PACU. (NCT02625181)
Timeframe: PACU recovery period

InterventionParticipants (Count of Participants)
Baseline Measurement139
CDS Email Recommendations1323
CDS Email + Real TIme Recommenations1343

[back to top]

Time to Discharge From the Postanesthesia Care Unit (PACU)

This is the number of minutes from admission to the PACU until discharge, assessed up to 2 days (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU

Interventionminutes (Mean)
Baseline Measurement266
CDS Email Recommendations264
CDS Email + Real TIme Recommenations266

[back to top]

PONV Incidence

The incidence of PONV (NCT02635828)
Timeframe: 24 hours after end of surgery

Interventionparticipants (Number)
Triple Therapy PONV Prohylaxis12

[back to top]

Incidence of Subjects Significant QTc Changes in the EKG

The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery (NCT02635828)
Timeframe: 24 and 120 hours/discharge after end of surgery

Interventionparticipants (Number)
Triple Therapy PONV Prohylaxis0

[back to top]

Number of Participants Completed All Study Procedures Over Seven Days

"The proposed study is a prospective, single-center, feasibility trial. The primary aim of this study is feasibility - specifically feasibility will be defined as completion of all study procedures over seven days.~For the primary aim, we assume an acceptable completion rate from strata of MEC/HEC or tumor types of all study-related procedures would be at least 70%. Assuming a true completion rate of 85%, a sample size of 50 patients would have an 80% power to detect an absolute difference of 15% at Type I error 0.05." (NCT03008213)
Timeframe: Through study completion, 7 days

Interventionparticipants (Number)
Netupitant and Palonosetron1

[back to top]

Functional Living Index Emesis (FLIE): Vomiting Sub-score

FLIE is a questionnaire validated to assess the impact of chemotherapy induced nausea and vomiting on patient's function and quality of life over the past 5 days. It consists of 18 items, with 9 items on nausea and 9 items on vomiting. Each question was rated using a Numerical Rating Scale (NRS) from 1 to 7. The total Vomiting sub-score ranges from 9 to 63, where a higher score indicates higher quality of life. We measured the change of vomiting sub-score from baseline to day 15.Wilcoxon rank sum test was used for analysis. (NCT03040726)
Timeframe: Baseline and Day 15

Interventionscore on a scale (Mean)
Blinded Intervention Group-12.5
Blinded Placebo Group-9.7

[back to top]

Index of Nausea, Vomiting and Retching: Total Experience Score

Index of Nausea, Vomiting, and Retching, which consists of 8 items asking about the patient's experience regarding nausea and vomiting over the past 12 hours. Each item included a 5-point Likert scale (0-4 points) with descriptive words. Total experience score ranged from 0-32 with higher score indicates more nausea/vomiting. We measured the change in score between day 5 and day 15. Wilcoxon rank sum test was used for analysis. (NCT03040726)
Timeframe: Day 5 and Day 15

Interventionscore on a scale (Mean)
Blinded Intervention Group-2.3
Blinded Placebo Group-2.5

[back to top]

Functional Living Index Emesis (FLIE): Nausea Sub-score

FLIE is a questionnaire validated to assess the impact of chemotherapy induced nausea and vomiting on patient's function and quality of life over the past 5 days. It consists of 18 items, with 9 items on nausea and 9 items on vomiting. Each question was rated using a Numerical Rating Scale (NRS) from 1 to 7. The total Nausea sub-score ranges from 9 to 63, where a higher score indicates higher quality of life. We measured the change of nausea sub-score between baseline 5 to day 15. Wilcoxon rank sum test was used for analysis. (NCT03040726)
Timeframe: Baseline and Day 15

Interventionscore on a scale (Mean)
Blinded Intervention Group.-16.6
Blinded Placebo Group-18

[back to top]

Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15

Average intensity of nausea over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10, where 0= none and 10= worse possible nausea. The total score ranged from 0-10. We measured the within-group change in nausea intensity from day 5 to day 15. Wilcoxon rank sum test was used for analysis. (NCT03040726)
Timeframe: Day 5 and Day 15

Interventionscore on a scale (Mean)
Blinded Intervention Group-2.0
Blinded Placebo Group-2.3

[back to top]

Complete Response (CR) Defined as no Emesis and no Rescue Therapy

Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy. (NCT03097588)
Timeframe: Up to 5 days post chemotherapy

InterventionParticipants (Count of Participants)
Supportive Care (NEPA)13

[back to top]

Complete Protection (CP) Rate Defined as CR Plus no Nausea

Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 264 hours of the study drug administration. (NCT03097588)
Timeframe: Up to 264 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
Supportive Care (NEPA)3

[back to top]

Time to Receiving First Rescue Medication and First Emesis

Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods. (NCT03097588)
Timeframe: Up to 264 hours

InterventionHours (Mean)
Mean time to first rescue medicationMean time to first emesis
Supportive Care (NEPA)1438.9

[back to top]

Time to First Emesis and Time to Receiving First Rescue Medication

Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods. (NCT03097588)
Timeframe: Up to 264 hours

InterventionHours (Median)
Median time to receiving rescue medicationTime to first emesis
Supportive Care (NEPA)148.4216

[back to top]

Number of Participants With Emetic Episodes and Received Rescue Agents (Delayed Phase)

The number of participants that had emetic episodes and received rescue agents (medications) during the delayed phase (for 145 hours up to 264 hours timeframe) (NCT03097588)
Timeframe: From 145 hours up to 264 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
The number of participants that had an emetic episodeThe number of participants that were given rescue meds
Supportive Care (NEPA)823

[back to top]

Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)

The number of participants that had emetic episodes and received rescue agents (medications) (for 0 to 24 hours timeframe of study drug administration) (NCT03097588)
Timeframe: Up to 24 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
Number of participants that had emetic episodesNumber of participants that were given rescue meds-
Supportive Care (NEPA)02

[back to top]

Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)

The number of participants that had emetic episodes and received rescue agents (medications) (acute phase: for 0 to 144 hours timeframe of study drug administration) (NCT03097588)
Timeframe: Up to 144 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
Number of participants who had an emetic episode in acute phaseNumber of participants who were given rescue meds in acute phase
Supportive Care (NEPA)013

[back to top]

Number of Participants With Emetic Episodes and Received Rescue Agents

The number of participants that had emetic episodes and received rescue agents (medications). (NCT03097588)
Timeframe: Up to 264 hours

InterventionParticipants (Count of Participants)
Number of participants who had emetic episodesNumber of participants who were given rescue meds
Supportive Care (NEPA)836

[back to top]

Mean Levels of Nausea Per Day Assessed by Chemotherapy Induced Nausea and Vomiting Questionnaire

The mean level of nausea per day assessed by chemotherapy induced nausea and vomiting questionnaire. The full range of nausea level score on the questionnaire was from minimum value of 0 to a maximum value of 10. 0= no nausea or vomiting, and 10= worst nausea and vomiting. Higher score means a worse outcome. (NCT03097588)
Timeframe: Up to 11 days

Interventionscore on a scale (Mean)
Supportive Care (NEPA)2.79

[back to top]

CR (Delayed Phase)

Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 145 hours up to 264 hours (delayed phase) of the study drug administration. (NCT03097588)
Timeframe: From 145 hours up to 264 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
Supportive Care (NEPA)1

[back to top]

CR (Acute Phase)

Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 144 hours (acute phase) of the study drug administration. (NCT03097588)
Timeframe: Up to 144 hours post-study drug administration on day 1

InterventionParticipants (Count of Participants)
Supportive Care (NEPA)12

[back to top]

Maximum Plasma Concentration (Cmax) of Netupitant

Mean values of maximum plasma concentration (Cmax) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. Cmax estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles (NCT03204279)
Timeframe: within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h

Interventionng/mL (Mean)
1 month to <3 months3 months to <6 months6 months to <12 months1 year to <2 years2 years to <5 years5 years to <12 years12 years to <18 years
Netupitant 1.33 mg/kg Plus Palonosetron60.876.013369.574.067.976.8

[back to top]

Maximum Plasma Concentration (Cmax) of Netupitant

Mean values of maximum plasma concentration (Cmax) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. Cmax estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles (NCT03204279)
Timeframe: within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h

Interventionng/mL (Mean)
3 months to <6 months6 months to <12 months1 year to <2 years2 years to <5 years5 years to <12 years12 years to <18 years
Netupitant 4 mg/kg Plus Palonosetron233255275266213274

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant

Mean values of area under the plasma Concentration versus time curve from time zero to infinity (AUC0-inf) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. AUC estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles. (NCT03204279)
Timeframe: within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h.

Interventionng*hr/mL (Mean)
patients 1 month to <3 months of agepatients 3 month to <6 months of agepatients 6 month to <1 year of agepatients 1 year to <2 yearspatients 2 years to <5 yearspatients 5 years to <12 yearspatients 12 years to <18 years
Netupitant 1.33 mg/kg Plus Palonosetron4460384976372276313526763107

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant

Mean values of area under the plasma Concentration versus time curve from time zero to infinity (AUC0-inf) of netupitant after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. AUC estimates are obtained by non-compartmental analysis of population model-predicted individual plasma concentration-time profiles. (NCT03204279)
Timeframe: within 168 hours after netupitant administration. A sampling windows approach will be used by collecting a single blood sample from each patient in one of these time windows: from 2 to 8 h, from 24 to 48 h, from 72 to 96 h and from 120 to 168 h.

Interventionng*hr/mL (Mean)
patients 3 month to <6 months of agepatients 6 month to <1 year of agepatients 1 year to <2 yearspatients 2 years to <5 yearspatients 5 years to <12 yearspatients 12 years to <18 years
Netupitant 4 mg/kg Plus Palonosetron1734086179886144041015412266

[back to top]

Percentage of Pediatric Patients With Complete Response During the Delayed Phase

Percentage of Pediatric Patients with complete response (CR, i.e., no emetic episodes and no rescue medication) during the delayed phase (> 24 to 120 h after the start of chemotherapy on Day 1) after a single oral netupitant administration, concomitantly with oral palonosetron, in pediatric cancer patients receiving HEC or MEC cycles. (NCT03204279)
Timeframe: > 24-120 hours after the start of chemotherapy on Day 1

InterventionParticipants (Count of Participants)
Netupitant 1.33 mg/kg Plus Palonosetron24
Netupitant 4 mg/kg Plus Palonosetron22

[back to top]

Number of Participants With Treatment-emergent AEs at Cycle 1

(NCT03403712)
Timeframe: At the end of Cycle 1 (each cycle is 21 days)

InterventionParticipants (Count of Participants)
Test Group121
Control Group122

[back to top]

Complete Response in Cycle 1 During the Overall Phase

defined as no emetic episodes [vomit or retch] and no rescue medication (NCT03403712)
Timeframe: 0-120 hours after the start of AC chemotherapy

InterventionParticipants (Count of Participants)
Test Group146
Control Group156

[back to top]

Complete Response in Cycle 1 During the Delayed Phase

defined as no emetic episodes [vomit or retch] and no rescue medication (NCT03403712)
Timeframe: 120 hour after the start of AC chemotherapy administration

InterventionParticipants (Count of Participants)
Test Group151
Control Group159

[back to top]

Complete Response in Cycle 1 During the Acute Phase

defined as no emetic episodes [vomit or retch] and no rescue medication (NCT03403712)
Timeframe: 24 hours after the start of AC chemotherapy administration

InterventionParticipants (Count of Participants)
Test Group173
Control Group179

[back to top] [back to top]

Number of Participants With Severe (i.e., CTCAE Grade ≥3) TEAEs Reported for ≥2% of Patients in Either Treatment Group and Overall Throughout the Study

(NCT03403712)
Timeframe: At the end of Cycle 4 (each cycle is 21 days)

InterventionParticipants (Count of Participants)
Test Group37
Control Group29

[back to top]

Number of Participants With Treatment-emergent AEs All Cycles

(NCT03403712)
Timeframe: At the end of Cycle 4 (each cycle is 21 days)

InterventionParticipants (Count of Participants)
Test Group184
Control Group187

[back to top]

Overall Percentage of Patients With NIDL Based on FLIE Scores for Cycles 1

"Percentage (including two-sided 95% CI using Wilson score method) of patients with NIDL based on FLIE scores (overall, by domain, and by individual item) are summarized by treatment group. NIDL was defined as a score greater than 108 points, 54 points, and 6 points for total FLIE score, domain score, and single item score, respectively. Differences between treatment groups for total FLIE score and domain scores (nausea and vomiting) were presented with two-sided 95% CIs using the CMH method adjusted for region and age class strata and also using Newcombe-Wilson's method without strata adjustment.~No Impact on Daily Life (NIDL) Based on Functional Living Index-Emesis (FLIE) Scores. The FLIE is a nausea and vomiting specific self report instrument comprised of two domains (nausea and vomiting) with nine identical items in each domain" (NCT03403712)
Timeframe: cycle 1

,
Interventionpercentage of participants (Number)
total scoreNausea domain scoreVomiting domain score
Control Group78.768.390.6
Test Group74.067.587.5

[back to top]

Average Nausea Scores (0-10) Repeatedly Measured by the Nausea and Vomiting Daily Diary/Questionnaire

The specific measure will be based on the by the single nausea item (scale 0-10, 0 is no symptoms, 10 is worst symptoms) of the Nausea and Vomiting Daily Diary/Questionnaire. Nausea scores (0-10) repeatedly measured by the Nausea and Vomiting Daily Diary/Questionnaire will be analyzed using the repeated measures analyses and growth curve models as described above for undesired sedation and increase in appetite. (NCT03578081)
Timeframe: Up to 1 year

Interventionscore on a scale (Mean)
Arm I (Fosaprepitant Dimeglumine, Olanzapine)0.8211364
Arm II (Placebo, Olanzapine)0.9177778

[back to top]

Total Frequency of Rescue Medication as Measured by the Nausea and Vomiting Daily Diary/Questionnaire

The specific measure will be based on the single item : number of extra nausea/vomiting pills taken (None, One , Twice, More than twice) of the Nausea and Vomiting Daily Diary/Questionnaire. (NCT03578081)
Timeframe: Over 5 Days per each of the 4 cycles

,
Interventionepisodes (Number)
ZeroOneTwoMore than two
Arm I (Fosaprepitant Dimeglumine, Olanzapine)361435017056
Arm II (Placebo, Olanzapine)354140516274

[back to top]

Potential Toxicities as Ascribed to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire

Potential toxicities includes nausea, undesired sedation, and undesired appetite, measured by three individual items ( nausea, undesired sedation, undesired appetite) of the Nausea and Vomiting Daily Dairy/Questionnaire(scale 0-10, 0 is no symptoms, 10 is worst symptoms). Incidences of toxicities will be summarized by type and by treatment arm. Incidences of toxicities will be compared between arms using a Chi-squared test or the Fisher's exact test as appropriate. In addition, undesired sedation and appetite increase as collected in the Nausea and Vomiting Daily Diary/Questionnaire will be analyzed by repeated measures analyses including descriptive statistics, graphical approaches, and growth curve models to account for the factor of day and time trend. (NCT03578081)
Timeframe: Up to 120 hours

,
InterventionParticipants (Count of Participants)
Overall No Appetite IncreaseOverall Any Appetite IncreaseAcute No Appetite IncreaseAcute Any Appetite IncreaseDelayed No Appetite IncreaseDelayed Any Appetite Increase
Arm I (Fosaprepitant Dimeglumine, Olanzapine)14018623591147179
Arm II (Placebo, Olanzapine)13618423684143177

[back to top]

No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and Delayed (24-120 Hours) Periods

The specific measure will be based on the proportion of patients with a value of 0, as measured by the single nausea item (scale 0-10, 0 is no symptoms, 10 is worst symptoms) of the Questionnaire. A modified intent-to-treat principle will be applied for statistical analysis of efficacy in evaluable patients. The proportions of patients with no nausea during the overall, the acute, and the delayed period will be summarized by treatment arm. They will be tested in a sequential manner, using a Simes gatekeeping procedure to maintain the overall significance level at the specified by the Lan-DeMets family of alpha spending function. The difference in no nausea proportions between arms will be estimated along with a one-sided 95% confidence interval. The tests and the confidence intervals will be constructed using normal approximation of the binomial distribution adjusted for the non-inferiority margin. (NCT03578081)
Timeframe: Up to 120 hours

,
InterventionParticipants (Count of Participants)
Overall No NauseaOverall Any NauseaAcute No NauseaAcute Any NauseaDelayed No NauseaDelayed Any Nausea
Arm I (Fosaprepitant Dimeglumine, Olanzapine)123203202124140186
Arm II (Placebo, Olanzapine)97223201119114206

[back to top]

Complete Response (CR) (no Emetic Episodes and no Use of Rescue Medication) During the Acute, Delayed and the Overall Periods as Measured by the Nausea and Vomiting Daily Diary/Questionnaire

"The specific measure will be based on the proportion of patients who answered None to both questions concerning Vomiting episode(None, Once, Twice, More than twice) and number of extra nausea/vomiting pills taken (None, One, Two, More than two) in the Nausea and Vomiting Daily Diary/Questionnaire. The CR rate for the overall, the acute, and the delayed period will be summarized by treatment arm and will be compared using a Chi-squared test. The difference in CR rates between arms will be estimated along with a 95% confidence interval." (NCT03578081)
Timeframe: Up to 120 hours

,
InterventionParticipants (Count of Participants)
Complete Response - >> OverallComplete Response - >> AcuteComplete Response ->> Delayed
Arm I (Fosaprepitant Dimeglumine, Olanzapine)179256193
Arm II (Placebo, Olanzapine)151247166

[back to top]

Total Functional Living Index-Emesis (FLIE) Score at Cycle 1

"The Functional Living Index - Emesis questionnaire is a validated patient reported outcome with the objective of assessing the impact of chemotherapy-induced nausea and vomiting on patient's daily function.~Questionnaire consists of a nausea domain and a vomiting domain of nine items each where the patient should rate how much nausea and vomiting have affected the quality of life. For each question the patient will rate how much nausea (or vomiting) has affected an aspect of his quality of life during the past five days. Each question uses a visual analogue scale (100 mm) and an ordinal scale (where 1= no emesis-7=a great deal). The minimum total score is 18 and the maximum total score is 126. Higher scores indicate less impairment on daily life as a result of nausea or vomiting. A FLIE total score > 108 indicates no impairment on daily life as a result of nausea or vomiting.~Assessed by patient following day 5 of each cycle." (NCT03649230)
Timeframe: Day 5 of cycle 1

Interventionscore on a scale (Mean)
Treatment109.2

[back to top]

Severity of Nausea on Day 5 (Change From Day 1)

"Question 1 of the daily evaluation of the Patient Diary (How much nausea did you experience on average during the last 24 hours?). Data was collected on a visual analogue scale. Scale ranges from 0 mm (no nausea) to 100 mm (always severe nausea)." (NCT03649230)
Timeframe: Days 1-5 (0 - 120 hours) of cycles 1, 2, 3, 4; each cycle is approximately 28 days

Interventionmm (Mean)
Cycle 1-7.1
Cycle 2-3.3
Cycle 3-1.4
Cycle 4-1.5

[back to top]